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High density lipoprotein cholesterol (HDL) and its component sphingosine-1-phosphate 
(S1P) protect against myocardial infarction. Recently, the SAFE (survivor activating factor 
enhancement) pathway, involving tumour necrosis factor (TNF) and the transcription factor 
signal transducer and activator of transcription 3 (STAT-3), has been identified as a key 
signalling pathway in cardioprotection, although the end effector remains unclear. Opening 
of the mitochondrial Permeability Transition Pore (mPTP) is a crucial initiator of cell death in 
the setting of myocardial infarction. We therefore hypothesised that HDL/S1P protect the 
heart by the activation of the SAFE pathway, and the subsequent inhibition of mPTP 
opening. 
Methods 
Isolated adult rat hearts were pre-treated with 10nM S1P followed by either mitochondrial 
isolation or 30 minutes of regional ischaemia and 2 hours of reperfusion. Respiratory 
parameters of the mitochondria were measured using a Clarke-oxygen electrode. Infarct size 
was determined using triphenyltetrazolium chloride staining. 
Isolated adult mouse cardiomyocytes (wildtype or STAT-3 cardiomyocyte deficient (KO)) 
were exposed to 2 hours of hypoxia with/without pre-treatment with native HDL (300mg/ml) 
or S1P (10nM).  Cell viability was assessed, and mPTP opening using 
TetraMethylRhodamine Methylester (TMRM) (normalised to the normoxic control). 
Mitochondrial STAT-3 levels were assessed using Western blotting.   
Results 
S1P improved respiratory control indices (state 3:state 4 respiration) in isolated rat heart 
mitochondria from 4.2±0.5 Arbitrary Units (AU) to 11.0±1.4 AU (p<0.05), and decreased 
infarct size from 25.8+/-3.1% to 4.6+/-1.4% of the area at risk (p<0.05).  
Cardiomyocyte viability under normoxic conditions was 84.3±1.5%. Hypoxia reduced viability 
to 61.0±2.5% (p< 0.05 vs. control). Cardiomyocyte viability was restored with S1P 
(80.4±1.4%) or native HDL (76.8±1.8%) (p<0.05 vs. hypoxia). TMRM fluorescence following 
hypoxia was 77±6 AU (p<0.05 vs. control), and restored to 95±4 AU in the S1P group and 
88.4±11.0 AU in the HDL group (p<0.05 vs. hypoxia). In the STAT-3 KO mice, no 
cardiomyocyte viability improvement or restoration of TMRM fluorescence was observed 
with either HDL or S1P. S1P also increased serine phosphorylation of mitochondrial STAT-3. 
Conclusions 
Both native HDL and S1P are cardioprotective, and our data strongly suggest that this effect 
is mediated via activation of the STAT3 component of the SAFE pathway, and subsequent 

























List of Figures 
 
Figure 1: Cause of death amongst individuals aged 15-59. .................................................................. 12 
Figure 2: Ischemic heart disease.. ......................................................................................................... 15 
Figure 3: Protective effect of ischemic preconditioning (IPC).. ............................................................ 16 
Figure 4: Summary of methods for conditioning the heart with ischaemia. ........................................ 17 
Figure 5: Basic Structure of a mature HDL cholesterol molecule. ........................................................ 19 
Figure 6: Simplified version of the synthesis and various fates of HDL cholesterol in the body. ......... 20 
Figure 7: Relationship between cholesterol levels and mortality.. ...................................................... 21 
Figure 8: Formation of an atherosclerotic plaque.. .............................................................................. 22 
Figure 9: Basic structure of S1P ............................................................................................................ 23 
Figure 10: Synthesis of Sphingosine-1-Phosphate (S1P) in the cell. ..................................................... 24 
Figure 11: The RISK pathway ................................................................................................................. 27 
Figure 12: the SAFE pathway. ............................................................................................................... 29 
Figure 13: Basic structure of a mitochondrion. .................................................................................... 30 
Figure 14: The Electron Transport Chain.. ............................................................................................ 31 
Figure 15: The Caspase pathway.. ........................................................................................................ 34 
Figure 16: Schematic diagram of the hypothesis . ................................................................................ 37 
Figure 17: Experimental Design of the project. .................................................................................... 39 
Figure 18: Langendorff retrograde perfusion apparatus. ..................................................................... 41 
Figure 19: Isolated rat heart mounted on a Langendorff apparatus. ................................................... 42 
Figure 20: Experimental protocols in the isolated heart. ..................................................................... 43 
Figure 21: Percoll mitochondrial isolation. ........................................................................................... 45 
Figure 22:   Buiret concentration-absorbance plot. .............................................................................. 46 
Figure 23: Clarke-electrode setup.. ....................................................................................................... 47 
Figure 24: Mitochondrial respiration in the Clarke-electrode apparatus. ............................................ 48 
Figure 25: Isolated adult mouse cardiomyocytes. ................................................................................ 50 
Figure 26: Experimental protocols for isolated mouse cardiomyocytes. ............................................. 51 
Figure 27: TMRM Fluorescence of isolated mouse cardiomyocytes.. .................................................. 53 
Figure 28: Absorption/emission spectra of TMRM. .............................................................................. 54 
Figure 29: FL-2 fluorescent histograms and FSC and SSC plots. ........................................................... 56 
Figure 30: Gated population (R2) of events registering little to no fluorescence. ............................... 57 
Figure 31: Setup of Gel electrophoresis plates.. ................................................................................... 59 
Figure 32: Set up of transfer system for western blot analysis. ........................................................... 60 
Figure 33: Ponceau staining of the membrane.. ................................................................................... 61 
Figure 34: Infarct size of isolated rat hearts subjected to regional ischaemia-reperfusion. ................ 64 
Figure 35: Respiratory Control Index (RCI) values of isolated rat mitochondria. ................................. 65 
Figure 36: Effect of S1P on cell viability in isolated wildtype cardiomyocytes subjected to 2 hours of 
hypoxia.. ................................................................................................................................................ 66 
Figure 37: Effect of HDL cholesterol on cell viability in isolated cardiomyocytes subjected to 2 hours 















Figure 38: Effect of S1P on TMRM fluorescence in isolated cardiomyocytes using a fluorescent 
microscope.. .......................................................................................................................................... 68 
Figure 39: Effect of S1P on TMRM fluorescence in cardiomyocytes using a flow cytometer.. ............ 69 
Figure 40: Effect of HDL cholesterol on TMRM fluorescence levels in cardiomyocytes exposed to 
hypoxia using a flow cytometry. ........................................................................................................... 70 
Figure 41: Effect of HDL cholesterol (300mg/ml) or S1P (10nM) on total STAT-3 (tSTAT) levels in 
mitochondria.). ..................................................................................................................................... 71 
Figure 42: Efect of HDL cholesterol (300mg/ml) or S1P (10nM) on serine phosphorylated STAT-3 
(pSTATSer) levels in mitochondria. ....................................................................................................... 72 
Figure 43: HDL Cholesterol and S1P have no cardioprotective effect in STAT-3 KO mice.................... 73 
Figure 44: Effect of HDL Cholesterol and S1P on mPTP opening in isolated cardiomyocytes from 
STAT-3 KO mice exposed to hypoxia.. ................................................................................................... 74 


















































List of Tables 
 
Table 1: Global impact of diseases, ranked by mortality. ..................................................................... 14 
Table 2: Expression of S1P receptor subtypes in different cardiovascular tissue types. ...................... 25 
Table 4: Proposed components of the mPTP........................................................................................ 33 
Table 5: Inclusion Criteria for Langendorff perfused rat hearts. .......................................................... 42 
Table 6: Flow cytometry settings for mPTP opening analysis. .............................................................. 55 
Table 7: Summary of functional recovery data. .................................................................................... 63 






























Chapter 1: Introduction 
 
1: CARDIOVASCULAR DISEASE 
 
1.1  GENERALITIES  
 
Cardiovascular disease (CVD) is a broad term including cardiac pathologies, such as 
hypertrophy, atrophy and ischaemia, as well as vascular pathologies such as hypertension 
and arterial stiffening. Globally, it is the leading cause of death and accounts for 31.5% of all 
deaths in females and 26.8% in males (1). CVD has traditionally been viewed, firstly as a 
disease of the aged, and secondly as a problem of the developed world. However, CVD is 
becoming more and more a problem that spans both age and location (2). This shift in 
demographics is attributable to the urbanisation of those in the developing world and the 
increase in risk factors in younger individuals.  According to the World Health Organisation 
(WHO), CVD varies between the 2nd and 3rd leading cause of death among individuals aged 
15-59 in high income countries (2) (Figure 1).  
 
 
Figure 1: Cause of death amongst individuals aged 15-59. High income countries are not separated by 
continent, and are used as a reference point for developing regions (as such ‘Americas’ and ‘Europe’ do 















The contribution of CVD to mortality among 15-59 year olds varies considerably in low and 
middle income countries. As can be seen in Figure 1, CVD is the largest contributor to 
mortality in low income countries in Europe, whilst it plays a substantially lesser role in Africa 
relative to its other burdens of disease. The burden of all diseases is strongly exaggerated in 
lower income regions, especially in Africa, and even though it may seem that CVD should be 
of little concern to Africa, it should be noted that 80% of the total deaths attributable to CVD 
occurred in developing countries. By way of example, in 2004 South Africa had 186 720 
deaths  attributable to CVD, whereas the UK (which has a slightly larger population) had only 
105 000. This is strongly correlated with the increase in urbanisation in Sub-Saharan Africa 
and the risk factors associated therein (3).  
Furthermore, many of the larger killers in Africa have been on the decline in recent years. 
The prevalence of HIV/AIDS in Sub-Saharan Africa (currently the leading cause of death in 
Sub-Saharan Africa) has been on the decrease since 2001, in line with the introduction of 
antiretroviral treatment (4). CVD on the other hand continues to rise at a rate of roughly 4.5% 
per year (3), and in the Western Cape area of South Africa it is already the leading cause of 
death (5).  
 
1.2  ISCHEMIC HEART DISEASE 
 
Of all the forms of CVD, ischemic heart disease (IHD) is the most lethal, accounting for 
12.2% of all cause mortalities (over 7 million people) worldwide (Table 1). In middle income 
countries IHD is the leading cause of death, whilst in low income countries it is second only 
































Table 1: Global impact of diseases, ranked by mortality. Ischemic heart disease (IHD) is the leading cause 
of death, having 1.5 million more deaths per year than the second biggest killer, cerebrovascular 
diseases (1). 
 
IHD is caused by a blockage in one of the coronary arteries supplying blood to the heart 
muscle. This can be caused by many factors, such as clot or spasm, and in all cases it 
results in the loss, or severe reduction, in supply of oxygen and nutrients to the affected 
tissue (Figure 2). This depletion initiates a series of cellular reactions known as the ischemic 
cascade (6). Briefly, adenosine triphosphate (ATP) synthesis fails due to the lack of oxygen. 
Without ATP, ion transport pumps cannot function adequately, causing an accumulation of 
calcium in the cell. Calcium excess causes oxidative damage and up regulates calcium 
dependent enzymes, such as phospholipases (7). These enzymes degrade cellular and 
mitochondrial membranes, which will result in either necrosis or apoptosis. Necrosis 
releases toxic cellular contents into the extracellular matrix and elicits a localised 
inflammatory response which induces further cell death in the surrounding tissue (8). 
   
The current treatment for IHD is alleviation of the blockage, either via physical means 
(angioplasty) or pharmacological means (thrombolytics), and subsequent restoration of 
blood flow (reperfusion). However, reperfusion itself paradoxically leads to cellular damage 
















Figure 2: Ischemic heart disease. Typical location and cause of ischemic heart disease is an 
atherosclerotic plaque in the coronary artery. Of note, the tissue highlighted in purple is at risk of death, 
but depending on the duration of the ischaemia only a proportion of it will infarct (irreplaceable death of 
tissue). (Picture sourced from (9)). 
 
1.2.1 Reperfusion Injury 
The detrimental effect of reperfusion is caused by the rapid restoration of blood flow, which 
brings oxygen and nutrients to the tissue. This results in generation of reactive oxygen 
species (ROS) (10), excess calcium release (10) and an inflammatory response (11). The 
degree of damage is positively correlated with the severity of ischaemia and the speed of 
reperfusion (12).  The damage from reperfusion injury may account for up to 50% of the 
infarct (dead tissue) following ischaemia (13).  As such, there is a clinical need to reduce 
reperfusion injury, via pharmacological or physical means, to improve the benefit of 
reperfusion against ischemic heart disease. In particular, limiting reperfusion injury is 
important in the setting of percutaneous coronary intervention (PCI) as this is a very rapid 






















2.1.1 Ischemic conditioning 
Two of the most powerful tools for acute protection against ischaemia-reperfusion injury are 
the phenomena known as ischemic preconditioning and ischemic postconditioning. Ischemic 
preconditioning was first discovered in the dog model in 1986, and involves the 
administration of short periods of sublethal ischaemia, followed by brief periods of 
reperfusion, prior to the index ischaemia (14). In ischemic postconditioning, short periods of 
sublethal ischaemia-reperfusion are delivered following the index ischaemia (15).  Ischemic 




Figure 3: Protective effect of ischemic preconditioning (IPC). Cross sectional slices of hearts stained with 
triphenyltetrazolium chloride (TTC) reveal viable tissue (bright pink), and infarcted tissue (light 
yellow/white). A significant reduction in infarct size can be observed following IPC  (orange bar) as 
compared to the control (red bar) (16). 
 
Ischemic conditioning can also be applied remotely, either to a separate section of the 
tissue, or to entirely different organ systems (17). This has allowed for the development of a 
third method of ischemic conditioning, known as perconditioning, wherein the sublethal 
ischaemia is administered to a separate organ during the ischemic attack. Figure 4 
















Figure 4: Summary of methods for conditioning the heart with ischaemia.  
 
Ischemic preconditioning requires prior knowledge of the ischemic event. It can be applied to 
patients undergoing elective PCI, coronary artery bypass surgery, or heart transplant surgery 
(18).  
Remote conditioning, performed by small episodes of ischaemia-reperfusion in an organ 
separate to the heart, can also protect against ischaemia-reperfusion injury, and it presents 
the advantage of not being invasive. Pilot studies with remote perconditioning in humans 
have shown promising results (19). 
Similarly, ischemic postconditioning can be applied in patients with acute myocardial 
infarction, and this concept has been successfully tested in a clinical setting only two years 
after the discovery of ischemic postconditioning (20). 
However, there are some limitations to ischemic conditioning. With the exception of remote 
conditioning, ischemic conditioning requires catheterisation in order to be performed; if 
conditioning is done incorrectly, it carries the risk of being more detrimental than protective. 
Therefore, it requires adequate access to medical facilities as well as trained staff and 
proper equipment. In 2006, the South African Medical Journal reviewed the hospital transfer 
times as well as the in-hospital waiting times of cardiovascular patients, and concluded that 
pre-hospital administration of thrombolytics (with PCI as a conjunctive therapy where 
necessary) could reduce treatment times by up to 130 minutes (21). As was mentioned in 
section 1.2.1 the duration of ischaemia has dramatic effects on patient outcome, and hence 
reducing time before treatment could make the difference between life or death. Therefore, 
pharmacological agents, mimicking ischemic conditioning, that can be prescribed to at risk 
individuals, either for acute or chronic periods of time, are much more desirable as it would 
















2.1.2 Pharmacological conditioning 
Most pharmacological conditioning strategies have been identified following the delineation 
of the signalling mechanisms in ischemic conditioning.  Many mediators that have been 
identified in animal models are physiologically derived: adrenergic antagonists (22) ,opioids 
(23), bradykinin (24),  phospholipids (25), inflammatory cytokines such as tumour necrosis 
factor alpha (26) and serum components such as erythropoietin (27). In a clinical setting, 
preconditioning with volatile anaesthetics has also shown to exert a marked benefit in 
patients undergoing off-pump cardiac procedures (28). Due to the physiological presence of 
many of these protective factors, an alternative target for treatment is to increase their basal 
levels, as opposed to a single bolus injection. As a consequence, they are less likely to 
present adverse side effects, especially if the agent remains within physiological ranges. 
This increase can be achieved either through medication or, in some cases, through 
changes to lifestyle.  
 
2.2 LIFESTYLE CHANGES 
 
Unhealthy lifestyles can contribute to up to 70% of cardiovascular deaths, whilst modest 
reductions in risk-associated behaviours can have exponential benefits (a 0.5% reduction in 
risk factors can result in as much as a 23% decrease in mortality) (29),(30). There is a 
further benefit to targeting lifestyles, as it is more cost-effective than medication (31) which 
makes it an ideal treatment strategy for low income countries. Positive lifestyle factors can 
either reduce the incidence of CVD or the severity of the attack, and in some cases it can do 
both. Ideal sleep duration (32), moderate consumption of alcohol (33), regular exercise (34) 
and a healthy diet all have protective effects. In particular, a diet high in green, leafy 
vegetables, low carbohydrates and pol unsaturated fats not only lowers detrimental Low 
Density Lipoprotein (LDL) cholesterol but may also increase protective High Density 
Lipoprotein (HDL) cholesterol levels (35).  
 
2.3 HDL CHOLESTEROL 
 
2.3.1 Structure and Function 
HDL cholesterol has three major constituents: apolipoprotein A (ApoA), cholesterol and 
phospholipids (Figure 5). ApoA is synthesised predominantly in the liver and secreted into 
the bloodstream. It then associates with free cholesterol and phospholipids to form disc 
















Figure 5: Basic Structure of a mature HDL cholesterol molecule, adapted from (36). 
 
In this form it is known as discoidal, or nascent HDL (Figure 6). There are key enzymes 
which then associate with the nascent HDL cholesterol that assist in its maturation. The 
nascent HDL continues to take up free cholesterol, while simultaneously converting the free 
cholesterol particles into cholesterol esters via an enzyme component, the Cholesterol 
Acyltransferase (LCAT).  The phospholipids are the acyl donors in the esterification of the 
cholesterol, and allow for the binding of cholesterol to ApoA (37). When sufficient cholesterol 
has been esterified, the structure of HDL is converted into a spherical shape, allowing it to 
accommodate more cholesterol. Once it has reached this spherical shape it is referred to as 
mature, or spherical, HDL and is the most common form of HDL cholesterol found in the 
plasma.  
 
Mature HDL cholesterol has two fates in the body, depending on the pathophysiological 
conditions. Under normal conditions, it is primarily involved in transport of cholesterol from 
the blood vessels and the tissues to the liver in order for it to be metabolised and excreted, 
in a process known as Reverse Cholesterol Transport. The cholesterol esters are transferred 
to apolipoprotein B via the cholesteryl ester transfer protein (CETP), resulting in the 
formation of low density, or very low density lipoproteins (LDL or VLDL). These molecules 
can then either be reabsorbed by the tissues, degraded by the liver or oxidised to form an 
atherosclerotic plaque. The cholesterol may also be recycled back into the bloodstream. 
When cholesterol is in excess, either via dietary intake or from the peripheral tissues (such 
as adipose tissue or an atherosclerotic plaque), HDL is used as a transport mechanism to 
transport the excess cholesterol to the liver for degradation into bile salts or excretion in the 



















Figure 6: Simplified version of the synthesis and various fates of HDL cholesterol in the body, modified 
from (36). 
 
2.3.2 HDL and cardiovascular disease 
The establishment of a link between high cholesterol level (hyperlipidaemia) and CVD has 
been known since the early 1950’s (38) . There have been multiple studies exploring the 
composition, level and changes thereof in different races, countries and socioeconomic 
backgrounds. The general consensus of these studies is that whilst a low total cholesterol 
level is ideal, equally important is the ratio of HDL cholesterol relative to the total cholesterol, 


















Figure 7: Relationship between cholesterol levels and mortality. Total cholesterol, on the left, shows a 
positive correlation with deaths per 1000 people per year. White bars are men without any evidence of 
cardiovascular problems, whilst the shaded bars are men with existing cardiovascular problems. There is 
a greater sensitivity to higher total cholesterol levels in patients with pre-existing cardiovascular 
conditions. An inverse pattern is seen with HDL cholesterol, on the right, with increasing levels having a 
protective effect. Again, this seems to be more exaggerated amongst men with pre-existing 
cardiovascular conditions (shaded bar) (39). 
 
A high ratio of HDL cholesterol reduces overall mortality risk, and reduces the incidence of 
CVD. It is important to distinguish that although low HDL cholesterol is a very good risk 
indicator of developing CVD (40), it is not merely a marker for the disease but actually plays 
an active role in the prevention of cardiovascular incidents (41). In addition to its role in 
cholesterol transport and elimination, it can stimulate endothelial nitric oxide synthase, which 
produces nitric oxide and leads to vasodilation which attenuates hypertension and various 
forms of stroke. Also, HDL cholesterol stimulates fibrinolysis, stalling the progression of 
fibrosis of the heart. It has anti-inflammatory properties via the stimulation of the 
cyclooxygenase-2 pathway (41). It has antioxidant properties, preventing the formation of 
oxidised LDL particles and attenuating apoptosis in endothelial cells (41). Finally, it plays a 
crucial role in preventing IHD. 
2.3.3 HDL and ischemic heart disease 
Low relative levels of HDL cholesterol are strong predictors of ischemic events (42). This is 
likely due to HDL cholesterols anti-atherosclerotic effects (Figure 8). Atherosclerotic plaques 
form when oxidised LDL cholesterol damages the arterial wall via its phospholipase activity. 
This results in recruitment of macrophages which scavenge the LDL cholesterol. This 
scavenging process converts the macrophages into foam cells. Foam cells lose their 
migratory ability and hence form a plaque at the location of the arterial damage. The foam 
cells themselves often lyse, resulting in release of more oxidised LDL cholesterol and 
therefore increasing the plaque size. HDL cholesterol can scavenge the oxidised LDL 

















Figure 8: Formation of an atherosclerotic plaque. Oxidised LDL cholesterol initiates plaque formation, 
whilst HDL cholesterol degrades foam cells and reduces plaque size (44). 
 
HDL cholesterol can also prevent plaque formation, through Platelet Activating Factor Acetyl 
Hydrolase (PAF-AH), one of its many enzymatic components (Figure 5). PAF-AH hydrolyses 
the phospholipase enzymes within oxidised LDL cholesterol, diminishing its capability to 
damage the arterial wall (45). 
2.3.4 Mechanisms involved in HDL induced cardioprotection 
HDL cholesterol improves prognosis following an ischemic event via its antioxidant, anti-
apoptotic, anti-inflammatory and anti-atherosclerotic abilities. However, the exact 
mechanism of action of HDL cholesterol’s protection against ischaemia remains unclear, 
although these effects may be mediated by its ApoA content (46). Another promising 
candidate is the lysophospholipid sphingosine-1-phosphate (S1P), a phospholipid 
component of HDL cholesterol (47). This is supported by evidence linking the protective 
effect of HDL cholesterol to activation of the S1P receptors (48) . Furthermore, it has been 
demonstrated that the levels of S1P found within HDL cholesterol inversely correlate with the 





















2.4.1 Structure and Function 
S1P is a sphingolipid comprised of an 18 length alkyl chain, phosphorylated at C1 and 
covalently bound to an amine group at C2 and a hydroxyl group at C3 (Figure 9).  
 
 
Figure 9: Basic structure of S1P (50). 
 
It is a component of the ceramide pathway (Figure 10), which exists in all cells. As such S1P 
is produced intracellularly throughout the body. Once produced, it can either be involved in 
internal signalling, or be secreted and involved in paracrine/autocrine pathways via one or 
more of its five receptor subtypes. 
The main secretors of S1P are the haematopoietic cells (platelets, erythrocytes, mast cells 
and leukocytes) and endothelial cells (51). Plasma S1P ranges in concentration from 200-
1000nM. These concentrations are 20 to 100 fold higher than the binding coefficients of the 
S1P receptors (52), however the majority of plasma S1P is bound to HDL cholesterol 
(~60%), with the rest either bound to albumin or LDL cholesterol. Only a small percentage of 
the S1P remains in suspension (53). Thus, only 1-2% of plasma S1P is biologically active, 
the majority of which is located in suspension, although S1P bound to HDL cholesterol is not 


















Figure 10: Synthesis of Sphingosine-1-Phosphate (S1P) in the cell. S1P is derived from the cell 
membrane via a series of reversible enzymatic reactions. S1P may also be released from extracellular 
HDL via action of sphingosine kinase 1. Although not represented in this image, most of the enzymes 
involved in S1P synthesis are membrane bound. Extracellular S1P may enter the cell via binding to one 
of its 5 receptors, or may pass directly through the membrane due to its non-polar lipid composition.  
 
S1P is found intracellularly in cardiomyocytes, fibroblasts and endothelial cells with relative 
uniformity (55). However, the degree of expression of the S1P receptor subtypes (which 
have unique, even antagonistic, functions) vary considerably function to the cell type (Table 
2) (56). Receptor expression level can also be induced to different degrees in these cells by 
external stimulating factors, such as beta-d-fructan, which promotes receptor 1 expression in 

















Table 2: Expression of S1P receptor subtypes in different cardiovascular tissue types (56). 
 
2.4.2 S1P and cardiovascular disease 
In terms of the cardiovascular system, S1P is known to play four major roles:  Mediation of 
cardiac electrophysiology, conflicting roles in hypertrophy, regulation of vascular function, 
and protection against ischemic insult (56).  
Administration of S1P in vivo increases heart rate (chronotropy) and decreases the force of 
contraction (inotropy) (58). This has been suggested to be a novel mechanism, independent 
of the adrenergic pathway, regulated via the S1P receptors. Whether the 
electrophysiological role of S1P is positive or negative remains somewhat controversial, 
although it is likely that it may be beneficial or detrimental depending on the physiological 
circumstances. This may also be true for the role of S1P in hypertrophy, with some studies 
showing an increase in hypertrophy biomarkers following S1P treatment (59), whilst others 
showing no increase in other hypertrophy biomarkers (60). 
The role of S1P in hypertrophy and electrophysiology of the heart is reported as both 
beneficial and detrimental, whereas the role of S1P in vascular function (it promotes vascular 
integrity and angiogenesis, and is crucial in migration and proliferation of endothelial cells 
(56)) and ischemic injury has only been reported as beneficial. 
2.4.3 S1P and ischemic heart disease 
Lecour et al first reported the cardioprotective effect of S1P against ischaemia-reperfusion 
injury in the isolated perfused rat heart (26), although S1P is also protective against ischemic 
injury in multiple organ systems besides the heart, including liver, kidney and lung (61). Both 
S1P and ceramide were reported as cardioprotective, and it was initially postulated that 
because they are intermediaries in sphingolipid signalling, they might converge on 
sphingosine as the active component. However, S1P is cardioprotective independent of 
sphingosine (62).  Since then, strong evidence has accrued for an essential role of S1P in 
many protective pathways against ischemic injury: Antagonists of S1P receptors can abolish 















release S1P following stimulus with ischemic preconditioning (63).  Unlike ischemic pre and 
postconditioning, S1P has the added benefits of being non-invasive and easy to administer 
so it is an ideal candidate for therapeutic investigation. It should be noted that ischemic 
preconditioning and S1P administration have an additive effect (64), meaning that either 
ischemic preconditioning can act independent of S1P, or that it only taps into a small portion 
of the protective ability of S1P. 
2.4.4 Mechanisms involved in S1P induced cardioprotection 
The protective effect of S1P is mediated via specific receptor subtype activation (65), and 
this also holds true for the S1P contained within HDL cholesterol (48). In the cardiovascular 
system, S1P exerts its cardioprotective effect via binding to either receptor subtype 1 or 2. 
There is also evidence for S1P having direct intracellular actions independent of its receptors 
(66), although whether this plays a role in cardioprotection remains to be elucidated 
(evidence showing loss of protection using receptor antagonists would suggest it does not 
(67)). What remains unclear is the mode of action intracellularly. Recent evidence has 
suggested a role for two key cardioprotective signalling pathways, namely the Reperfusion 
Injury Salvage Kinase (RISK) pathway (68), and the Survivor Activating Factor Enhancement 
(SAFE) pathway (69), via the activation of Akt and STAT-3, respectively. However, it is 
unclear what the end effectors of S1P-induced activation of these signalling pathways are. 
 
3: SIGNALLING PATHWAYS IN CARDIOPROTECTION 
 
Two powerful prosurvival pathways exist in the heart: the Reperfusion Injury Salvage Kinase 
(RISK) pathway (70) and, the Survival Activating Factor Enhancement (SAFE) pathway (71). 
Whether these two pathways work in concert is still unclear in the literature, however both 
have been found to play a crucial role in ischemic preconditioning (70), (72) and 
postconditioning (73), (74), (75).  
 
3.1 THE RISK PATHWAY 
 
The RISK pathway was first described in 2004 (76), and is comprised of two important 
survival kinases (Figure 11). Firstly, protein kinase B (Akt), activated by phosphatidylinositol-
3-OH kinase (PI3K). And secondly, the p42/p44 extracellular signal-regulated kinases (Erk 
1/2), activated by mitogen-activated protein kinase kinases (MEK) (76).  
The RISK pathway is only activated at reperfusion, however its components can also be 
activated before the index ischaemia. Prior to ischaemia, PI3K can be activated by various 
G-Protein Coupled Receptors (GPCR) (77), including insulin (78), bradykinin and opioid 
receptors (79). This sets off a phosphorylation cascade (Figure 11) that results in activation 
of endothelial Nitric Oxide Synthase (eNOS) and production of Nitric Oxide (NO). NO, via 
Guanylyl Cyclases (GC) and subsequent production of cyclic Guanylyl Monophosphate 
(cGMP), activates Protein Kinase G (PKG) which exerts a protective effect on the 
mitochondrion, via opening of the mitochondrial K ATP channel and low level production of 
reactive oxygen species (ROS) (80),(81). This low level production of ROS primes the 

















Figure 11: The RISK pathway (82). Abbreviations as described in the text.   
 
At reperfusion, the RISK pathway is activated, inhibiting Glycogen Synthase Kinase 3 beta 
(GSK3β) and the mitochondrial permeability transition pore (mPTP), via activation of the 
PI3K and MEK signalling cascades. The exact effect that the RISK pathway has on the 
mitochondrion will be detailed in section 4.  
The RISK pathway can be activated by preconditioning (70), S1P (64) and HDL cholesterol. 
(However HDL cholesterol has only been shown in the context of cellular migration and 
proliferation, and not in cardiac cell lines) (83).  
 
3.2 THE SAFE PATHWAY 
 
The Survivor Activating Factor Enhancement (SAFE) pathway is a more recently discovered 
pathway (Figure 12), however some of its components are well established as prosurvival 
molecules and required for ischemic preconditioning (71). At the core of the SAFE pathway 















activated upon phosphorylation, and in the case of the SAFE pathway this phosphorylation is 
induced by tumour necrosis factor alpha (TNF). 
 
3.2.1 TNF 
TNF is a pro-inflammatory cytokine component of the innate immune system. Ischaemia-
reperfusion elicits an inflammatory response which results in the release of TNF from various 
cells, including macrophages and cardiac fibroblasts (84). As such, TNF is used as a 
prognostic marker for severity of ischaemia (85), and is associated with a poorer prognosis 
and larger infarct size (86). However, TNF can paradoxically be cardioprotective as a 
preconditioning agent (26). This paradox has been recently resolved by Lacerda et al (74), 
who demonstrated that TNF’s effect is receptor dependent. At high concentrations, TNF 
binds to receptor type 1 and is detrimental, whereas at low concentrations it binds to 
receptor type 2 and is cardioprotective. Binding of TNF to its receptor type 2 initiates STAT-3 
phosphorylation and is the first stage in the SAFE pathway (87) (Figure 12).  
3.2.2. STAT-3 
Two STAT isoforms are found in the heart, STAT-1 and STAT-3, and they have antagonistic 
effects; STAT-3 activation is anti-apoptotic, whilst STAT-1 promotes apoptosis (88). STAT-3 
can be activated by various factors, such as ischemic conditioning (mice with a genetic 
depletion of STAT-3 cannot be preconditioned (89) nor postconditioned (74)), ethanolamine 
(90), the cannabinoid receptors (91), the interleukins (92) and potentially even the RISK 
pathway (93). STAT-3 may also be activated by both HDL cholesterol and S1P (69). 
However, it remains unclear as to whether the above stimulants are also mediated via TNF 
and its receptors. Regardless of the receptor type, ligand binding results in the activation of 


















Figure 12: the SAFE pathway. Tumour Necrosis Factor (TNF) binds to its type 2 receptor. This activates 
Janus Kinase 2 (JAK), which initiates the STAT-3 signalling cascade.  
 
3.2.3 Downstream targets of the SAFE pathway 
There are two possible fates for STAT-3 following phosphorylation, depending largely on the 
residue that is phosphorylated. In the classic pathway, STAT-3 is phosphorylated at tyrosine 
705 (pSTATTyr), which causes it to homodimerise (94). Homodimerisation exposes a 
nuclear translocation signal allowing it to enter the nucleus. Once in the nucleus it is 
phosphorylated further at serine 727 (pSTATSer) and becomes activated as a transcription 
factor for prosurvival genes such as Manganese Superoxide Dismutase (MnSOD) and 
inducible Nitric Oxide Synthase (iNOS) (95).  
More recently, STAT-3 has also been discovered in the mitochondria (96), leading to the 
updated pathway which proposes that the location of STAT-3 phosphorylation may 
determine its fate: cytoplasmic phosphorylation of STAT-3 at its serine residue results in 
translocation to the mitochondria, whilst STAT-3 phosphorylated at the tyrosine residue 
follows a more classical nuclear route (97).  Furthermore, recent evidence has suggested 
that STAT-3 may not even need to be phosphorylated or dimerised in order to enter the 
nucleus (98), although tyrosine phosphorylation is still required for transcriptional activity. 
Thus, in the new model, pSTATTyr translocates to the nucleus and acts as a transcription 
factor, whilst pSTATSer translocates to the mitochondria (99), where it has an anti-apoptotic 
effect, via inactivation of the proapoptotic molecule Bcl-2-associated death promoter (BAD) 
(87). What decides whether cytosolic STAT-3 is phosphorylated at its serine or tyrosine 















4: THE MITOCHONDRION 
 
The Mitochondrion is a distinct vesicle within the cell responsible primarily for ATP synthesis 
(100), although it also plays a vital role in calcium retention and regulation of apoptosis. Due 
to their high energy requirements, mitochondria are abundant in cardiomyocytes, accounting 
for roughly 30% of the total cell volume (101). The mitochondria within a cardiomyocyte are 
subdivided into 3 distinct populations: subsarcolemmal (SSM), interfibrillar (IFM) and 
perinuclear (102). SSM are located just below the cell membrane and are more responsive 
to cellular signalling and stresses (103), whilst IFM are stacked between the myofibrils and 
have higher respiration rates due to their proximity to the high energy demanding myofibrils 
(104). Perinuclear, as the name suggests, are located in proximity to the nucleus. Even 
though these noticeable differences exist between the different populations of mitochondria, 
their basic structure and function remain the same. 
 
4.1 STRUCTURE AND FUNCTION 
 
The mitochondrion is composed of two membranes, an outer membrane and an inner 
membrane (Figure 13). The outer membrane acts to compartmentalise the mitochondrion 
from the cytoplasmic elements, and excludes all molecules larger than 1500 Daltons (105). 
Between the outer membrane and the inner membrane lies the intermembrane space.  
 
 
Figure 13: Basic structure of a mitochondrion. The entire mitochondrion is encapsulated by the outer 
membrane. Within the mitochondrion, the inner membrane invaginates towards the central matrix to form 
cristae (106).  
 
The inner membrane is divided into two regions: boundary regions which run parallel to the 















invaginate into the matrix, or centre, of the mitochondrion and are the site of the electron 
transport chain (ETC) (101). Within the matrix metabolic enzymes, as well as mitochondrial 
DNA and RNA, are housed. The matrix is also used for calcium storage.  
4.1.1 The electron transport chain 
The ETC consists of 4 enzymatic subunits, bridged by 2 electron carriers, and an ATP 
generating hydrogen ion pump. The role of the 4 subunits is to actively transport hydrogen 
ions from the matrix to the intermembrane space (Figure 14), using energy provided via 
electrons donated by nicotinamide adenine dinucleotide hydroquinone (NADH) or flavin 
adenine dinucleotide hydroquinone (FADH2) (sourced from the Krebs cycle). 
 
 
Figure 14: The Electron Transport Chain. Energy is provided from the Krebs cycle in the form of NADH or 
FADH2. Electrons are donated at either Complex I or II depending on the substrate being utilised. 
Transferral of the electrons along the chain drives the proton pumps establishing a membrane potential. 
This in turn is used to drive the ATP synthase ion pump (107).   
 
This hydrogen gradient, also referred to as a proton motive force or membrane potential 
(∆ʊ ), powers ATP generation. Hydrogen ions flow through the ATP Synthase ion pump 
















4.1.2 Calcium retention 
Under normal physiological conditions there is a natural influx and efflux of calcium within 
the mitochondria in order to maintain homeostasis of the cell, and regulate ATP production. 
Calcium ions (Ca2+) increase in cardiomyocytes when they are experiencing higher 
contractile force. Because the enzymes of the ETC are also dependent upon Ca2+, there is a 
subsequent influx into the mitochondrion to drive their activity and increases their ATP output 
(108) in order to supply more energy for contraction.  It is further hypothesised that this 
mechanism of Ca2+ uptake and release may propagate the contractile signal along the 
cardiomyocyte (109). However in pathological situations, such as during ischemic injury, the 
mitochondria are also involved in Ca2+ retention in response to stress (108). Most calcium is 
stored within the sarcoplasmic or endoplasmic reticulum of the cell. Mitochondria are 
positioned in proximity to Ca2+ release sites and are able to absorb any Ca2+ released from 
these reticula (110). Inside the mitochondrion the Ca2+ is converted to calcium phosphate for 
storage in the matrix. Calcium phosphate precipitates within the matrix allowing for a greater 
degree of calcium storage than if it remained in solution (A single mitochondrion can store up 
to 1M of calcium, although the majority of this is in precipitate and hence has no effect on ion 
gradients (111)). Even though the precipitation of calcium is engineered to minimise 
interference with the ETC machinery, the role of mitochondria as calcium absorbers under 
stressful conditions will still take precedence over ATP production by the ETC (112).  
Mitochondria will continue to take up calcium to the point that overload occurs and the 
mitochondria eventually lyse, initiating cell death (113). 
  
4.2 MITOCHONDRIA AND CELL DEATH 
 
The mitochondria play a pivotal role in regulation of cell death; both apoptosis and necrosis. 
Cell death, mediated by mitochondria, can be activated by growth factors, hypoxia, oxidative 
stress and DNA damage (114). Mitochondria can induce cell death either via generation of 
ROS or opening of the mitochondrial permeability transition pore (mPTP). The 
consequences to the mitochondrion of opening of the mPTP are loss of membrane potential, 
swelling and eventual lysing (113). It is the mitochondrion’s role in cell death that is targeted 
by the RISK pathway, and potentially by the SAFE pathway. Although, the components 
which regulate cell death are also integral parts of the mitochondria’s native functions.  
4.2.1 Oxidative stress 
Mitochondria are the primary source of ROS (between 0.2 and 2% of oxygen consumed by 
mitochondria end up as superoxides (115)) and are usually fairly efficient at scavenging 
ROS via the enzymes MnSOD, catalase and glutathione peroxidase (116). Low levels of 
ROS production are important for ischemic preconditioning (117), and are a consequence of 
activation of the RISK pathway (118). In theory, low levels of ROS change the redox state of 
the cell, which results in structural and functional changes in certain proteins involved in cell 
survival (119), priming the system so that it is prepared for greater ROS exposure. However, 
in the absence of preconditioning and when a greater imbalance occurs, usually due to an 
increase in ROS production such as during reperfusion (120), the ROS scavenging enzymes 
can no longer cope with the excess ROS, and ROS become free to oxidise DNA and 















4.2.2 The mitochondrial permeability transition pore 
The mPTP is a voltage-dependent pore which allows for the passage of molecules up to 
1500 Daltons in size (122) into and out of the mitochondrion and the matrix. It is not known 
what proteins form the pore although there is evidence, summarised in Table 3, for the 
involvement of Cyclophilin D, the Voltage Dependent Anion Channel (VDAC) and Adenine 




Evidence For Evidence Against 
Cyclophilin D 
 Cyclophilin D knock outs are 
insensitive to mitochondrial swelling 
(124) 
 Inhibition of Cyclophilin D with 
pharmacological agents inhibits mPTP 
activity (125) 
 Reconstituted Cyclophilin D and ANT 
complexes can function as an mPTP 
(126) 
  
 Cyclophilin D knock outs 
still contain a functioning 
mPTP, only less 
sensitive to external 
stimuli such as Ca2+ 
(127)   
VDAC 
 Anti-VDAC antibodies inhibit mPTP 
opening (128) 
 VDAC immunoprecipitates with 
Cyclophilin D (129) 
 Increases in VDAC expression lead to 
increased mPTP sensitivity (130) 
 
 VDAC is permeable to 
solutes of 1500 Daltons 
in its closed state (131) 
 Reconstituted 
Cyclophilin D and ANT 
complexes can function 
as an mPTP (126) 
 
ANT 
 ANT inhibitors block mPTP opening 
(132) 
 ANT interact  with Cyclophilin D in the 
mitochondrial membrane (133) 
 Increases in ANT expression lead to 
increased mPTP sensitivity (130) 
 
 ANT knock outs still 
exhibit normal mPTP 
responses (134) 
Table 3: Proposed components of the mPTP. 
 
Under basal conditions the pore remains closed in order to maintain the membrane potential 
between the matrix and the intermembrane space of the mitochondrion. Upon stimulation, 
the pore opens and water floods into the matrix due to its hyperosmolarity. The matrix 
swells, deforming the cristae to account for the increased volume size and uncoupling the 
ETC. As the inner mitochondrial membrane expands, the more rigid outer membrane 
ruptures, releasing various proapoptotic factors (section 4.2.3) into the cytoplasm (114). 
Prevention of opening of the mPTP is seen as the endpoint for ischemic preconditioning, 
postconditioning (135) and the RISK pathway (118). It has recently been reported that ROS 
mediated opening of the Mitochondrial K ATP channel may delay pore opening, providing 

















4.2.3 Proapoptotic factors 
Once the mitochondria have lysed and the outer membrane permeabilised, an irreversible 
path towards cell death is set in motion (137). The disruption of the outer mitochondrial 
membrane has three consequences: disruption of the ETC, activation of the caspase 
apoptotic pathway and release of proapoptotic factors (independent of the caspase 
pathway). 
The ETC is dependent upon integrity of the inner and outer mitochondrial membranes and 
subsequent maintenance of the hydrogen gradient (and accompanying pH gradient) in order 
to power the ATP Synthase ion pump (Figure 14). Disintegration of the outer mitochondrial 
membrane ablates the hydrogen gradient, reducing or even completely disabling the 
mitochondrion’s ability to generate ATP for the cell. It also uncouples the crucial spatial 
orientation of the components of the ETC, such as Complexes I-III and cytochrome c. 
 
Cytochrome c, an electron shuttle in the ETC (Figure 14), is thus released into the cytosol 
and activates the caspase apoptotic pathway via binding to caspase-9 and forming an 
‘apoptosome’ (138). This activates caspase-9, which in turn activates caspase-3 (Figure 15). 
Caspase-3 then exerts proteolytic effects within the cell, dismantling and salvaging the 
components of the cell.    
 
Figure 15: The Caspase pathway. When the mitochondrion lyses, various proapoptotic factors are 
released (AIF=Apoptosis Inducing Factor, EndoG=EndonucleaseG). Some directly activate the caspase 
pathway, whilst others inhibit the inhibitors of the caspase pathway, ensuring its activation (139). 















The caspase pathway is kept in a constant state of inhibition by the Inhibitors of Apoptosis 
(IAP) proteins. Dissolution of the mitochondrion also releases Smac and Htr2A proteins, 
which disable the IAPs and allow for activation of the caspase pathway (140)(141). 
 
The mitochondrion also releases proapoptotic factors that are independent of the caspase 
pathway, most notably Apoptosis Inducing Factor (AIF) (142) and endonuclease G (EndoG). 
AIF is a misnomer as its native function is to scavenge ROS, however when released from 
the mitochondrion it translocates to the nucleus and initiates chromatin condensation and 
DNA fragmentation (143). Ischemic preconditioned hearts exhibit lower levels of AIF in the 
cytoplasm and nucleus (supporting the crucial role of maintenance of mitochondrial integrity 
in cardioprotection) (144). EndoG has a similar role to AIF, in that is involved in DNA 
fragmentation when released from the mitochondrion (145), whilst its native function is 



































Chapter 2: Hypothesis and Objectives 
 
Ischemic heart disease is the leading cause of death worldwide. Multiple lifestyle factors 
contribute to the burden of disease, including smoking, diet, lack of exercise and alcohol 
consumption. These lifestyle factors can lead to alterations in the cholesterol profile, 
increasing LDL cholesterol and lowering HDL cholesterol levels. HDL cholesterol, and its 
major constituent S1P, can protect against ischaemia-reperfusion injury but the mechanisms 
of protection remain unknown. Our recent work suggests that S1P protects via the activation 
of the powerful prosurvival SAFE pathway, which involves the activation of STAT-3. 
Mitochondria are important constituents in the regulation of cell fate during myocardial 
infarction, and the inhibition of mPTP opening plays a critical role in limiting cell death from 
ischaemia-reperfusion injury. However, whether HDL cholesterol, S1P and the SAFE 




We hypothesised that HDL cholesterol, and its component S1P, confer cardioprotection 
against ischaemia-reperfusion injury via the inhibition of mPTP opening (Figure 16). 
Furthermore, we proposed that this effect is mediated via the activation of STAT-3, an 







































To answer this hypothesis, the following two objectives will be pursued: 
 
2.1 DO HDL CHOLESTEROL AND S1P HAVE AN EFFECT ON THE 
MITOCHONDRIA? 
 
To explore whether HDL cholesterol or its constituent SIP confer cardioprotection via the 
inhibition of mPTP opening two parameters will be assessed. Firstly, mitochondrial function 
will be measured using a Clarke-electrode in mitochondria extracted from the isolated rat 
heart pretreated with HDL cholesterol/S1P. Secondly, the opening of the mPTP will be 
assessed using flow cytometry or fluorescent microscopy techniques in isolated mouse 
cardiomyocytes subjected to a hypoxic insult, and pretreated with HDL cholesterol or S1P. 
  
2.2 ARE THE EFFECTS OF HDL CHOLESTEROL AND S1P REGULATED VIA THE 
SAFE PATHWAY? 
 
To answer this objective mPTP opening will be assessed in isolated cardiomyocytes from 
the cardiomyocyte specific STAT-3 deficient mouse. Similar to their wildtype controls, STAT-
3 deficient cardiomyocytes will be isolated and subjected to a hypoxic insult with or without 
pretreatment with HDL cholesterol or S1P. Furthermore, STAT-3 activation in the 
















Figure 17: Experimental Design of the project (abbreviations as described in the text).  
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Chapter 3: Materials and Methods 
 
1: ANIMALS  
 
All experiments involving animals were approved by the Health Science Faculty Animal 
Ethics Committee, University of Cape Town (Project numbers 009/015, 009/030 and 
009/052). Animals were housed and treated in accordance with the Guide for Care and Use 
of laboratory Animals Eighth Edition, published by the US National Institute of Health 
Publication (147). Animals were bred in the Animal Unit of the University of Cape Town, and 
allowed access to food and water ad libitum.  
Male Long-Evans rats weighing 250-300g were used for the isolated rat heart model. Rats 
were used because the isolation of mitochondria via the Percoll method does not yield a very 
high concentration of mitochondria. Hence, it would not have been feasible to isolate 
mitochondria from mouse hearts for analysis of respiratory parameters, as the yield would be 
too low.  
In contrast, a mouse model was used in isolated cardiomyocyte studies as it allowed us to 
compare cardiomyocyte specific STAT-3 deficient (STAT-3 KO) mice versus their wildtype 
controls. Ideally, controls should be littermate controls, but due to availability and time 
constraints this was not possible. Thus, male c57black6 mice aged between 12-16 weeks 
were used as controls. STAT-3 KO mice were created from a c57black6 strain by crossing 
homozygous floxed STAT-3 mice with heterozygous Myosin Light Chain 2V (MLC2V) driven 
Cre recombinase mice, as previously described (148). MLC2V is only expressed in 
ventricular cardiomyocytes (149), and as such the resultant STAT-3 KO mice are ventricular 
cardiomyocyte specific. 
 
2: ISOLATED RAT HEART MODEL 
 
2.1 LANGENDORFF RAT HEART PERFUSION 
 
Male Long-Evans rats were anaesthetised with 60mg/kg sodium pentobarbital via 
intraperitoneal injection. Rats were allowed to succumb to anaesthesia and were tested for 
sufficient depth of anaesthesia via the lack of the pedoreflex and changes in breathing rate. 
Thereafter, the chest cavity was opened, and the heart excised and mounted on the 
Langendorff retrograde perfusion apparatus (Figure 18) via cannulation of the aorta to a 20 
gauge blunted needle (Figure 19). Because the buffer is entering via the aorta, the 
Langendorff system is a retrograde perfusion model (For a detailed review on retrograde 
















Figure 18: Langendorff retrograde perfusion apparatus. 
 
The left atrium was surgically opened and an inflatable liquid-filled balloon was inserted into 
the left ventricle to measure functional parameters (Figure 19). The inflatable balloon was 
inflated using distilled water, and connected to a pressure transducer (Lasec). The pressure 
transducer converted the pressure changes in the balloon into electrical signals, which were 
in turn translated into functional parameters via a chart recorder (Lectromed). Hearts were 
perfused with Krebs-Henseleit buffer (appendix 1) and allowed to stabilise for 30 minutes. 
Pressure was maintained via a constant load of one metre high Krebs-Henseleit buffer 
(Figure 18). Temperature was measured with a thermocoupled wire (Physitemp, NJ, USA) 
inserted into the pulmonary artery, and connected  a Digitron 2600T temperature sensor 

















Figure 19: Isolated rat heart mounted on a Langendorff apparatus. Hearts are perfused via the aorta. 
Ventricular contraction and heart rate are measured via the insertion of a balloon into the left ventricle. 
Flow rate is determined via collection of effluent from the pulmonary vessels. Temperature is monitored 
using a temperature probe inserted into the pulmonary artery (adapted from (151)). 
 
Functional parameters were measured at 5, 10, 20 and 30 minute intervals during the 
stabilisation period to ensure the inclusion criteria (as detailed in Table 4) were met. 
Functional parameters were also measured after 5 minutes, 30 minutes and 120 minutes of 
reperfusion. To evaluate the functional parameters of the heart, the left ventricular systolic 
pressure and the left ventricular diastolic pressure were measured, and expressed as the 
difference between the two, namely the left ventricular developed pressure (LVDP). 
 
Criterion Inclusion Parameter 
  
Heart Rate 260-410 beats per minute 
Left Ventricular Developed Pressure 70-120 mmHg 
Left Ventricular Diastolic Pressure 2-10 mmHg 
Coronary Flow 8-18 ml per minute 
Rate Pressure Product 21 000 - 36 000 
Table 4: Inclusion Criteria for Langendorff perfused rat hearts. Hearts which did not fall within the 
inclusion parameters by the end of the 30 minute stabilisation period were excluded from the study. 
 
2.2 EXPERIMENTAL PROTOCOLS 
 
Following the stabilisation period, hearts were perfused with Krebs-Henseleit buffer with or 















(Figure 20). The concentration of 10nM was in line with the rest of the experiments in this 
thesis and was previously established as the optimum protective concentration in our 
laboratory (152). Immediately thereafter, some hearts were processed for Percoll 
mitochondrial isolation, whilst others underwent 30 minutes of regional ischaemia via 
occlusion of the left anterior descending artery. 3/0 silk ligature, attached to a 16mm 
curved atraumatic needle (Tyco healthcare), was threaded through the ventrical tissue 
behind the left anterior descending artery and tied tightly to induce ischaemia. After 30 
minutes, the ligature was released to allow for reperfusion for 120 minutes. These hearts 
were then removed and processed for infarct size analysis.  
 
 
Figure 20: Experimental protocols in the isolated heart. Arrows indicate points of removal for infarct size 
analysis in A and B and mitochondrial isolation processing in C and D. S1P = 10nM Sphingosine-1-
phosphate. 
 
2.3 INFARCT SIZE ANALYSIS 
 
Just prior to collection, the left coronary artery was re-ligated and the heart was perfused 
with 2% Evans blue. Non-ischemic tissue was stained blue, while the ischemic tissue 
remained unstained. Hearts were then immediately removed and frozen. After 24 hours, 
hearts were sectioned perpendicular to the septal wall using a surgical blade (5-6 slices per 
heart). Heart slices were incubated in sodium phosphate buffer (appendix 1) containing 1% 
w/v triphenyltetrazolium chloride (TTC) at 37°C, pH 7.4 for 15 minutes. TTC stains the viable 
tissue pink, and the infarcted tissue white/light yellow. Sections were then digitally scanned 
and analysed using planimetry. Infarct size was expressed as a percentage of tissue 















3: RESPIRATORY STUDIES IN ISOLATED RAT HEART MITOCHONDRIA 
 
3.1 PERCOLL MITOCHONDRIAL ISOLATION 
 
The Percoll mitochondrial isolation protocol was adapted from Costa and colleagues (153). 
Following isolation and perfusion (alone or with 10nM S1P), hearts were immediately 
removed from the Langendorff apparatus and resuspended in approximately 25ml of wash 
buffer (appendix 2) at 4°C. Hearts were minced lightly with surgical scissors. Wash buffer 
was then drained off and replaced 4 times to wash out any Krebs-Henseleit buffer, blood or 
other contaminants. Desiccated hearts were then resuspended in 2ml of Nagarse Type XXIV 
(at a concentration of 1mg/ml) and minced finely with scissors for 30-45 seconds at room 
temperature. Nagarse is a protease that allows for the extraction of both SSM and IFM 
mitochondrial fractions. Nagarse was then diluted out with the addition of 20ml bovine serum 
albumin buffer (appendix 2) in order to prevent damage to the mitochondrial proteins 
themselves.  Hearts were homogenised with 4 upward and do nward strokes of an 
automated Teflon pestle, on ice. Homogenate was centrifuged in 50ml Falcon centrifuge 
tubes (Adcock-Ingram) at 1700g for 2 minutes (All centrifugations were performed at 4°C). 
Time taken from removal of the heart from the Langendorff system to centrifugation was less 
than 4 minutes (a crucial time point in order to obtain viable mitochondria). Following 
centrifugation, the supernatant was retained and spun at 900g for a further 5 minutes. The 
crude mitochondrial pellet obtained may still contain cell membrane, peroxisome and 
lysosome contamination. Crude mitochondrial pellets were resuspended in 2ml of wash 
buffer. In order to get a purified mitochondrial fraction, this suspension was then spun 
through a Percoll gradient. Percoll is an inert density gradient that uses differences in size 
and buoyant density to fractionate cellular organelles (154). It is the gold standard of 
mitochondrial isolation, and produces the most pure form of isolated mitochondria currently 
possible. 40ml of 26% Percoll gradient (appendix 2) was transferred into a 50ml 
ultracentrifuge tube, and the resuspended crude mitochondrial preparation was then layered 
on top of this and centrifuged at 40 000g for 30 minutes. This resulted in the formation of two 
distinct bands (Figure 21). The lower band, which contained purified mitochondria, was 
extracted using a Pasteur pipette and resuspended in 40ml of EGTA-free buffer (appendix 
2). Samples were then centrifuged at 10 000g for 10 minutes to wash out any remaining 
Percoll, as this would otherwise interfere with analysis of the respiration parameters. The 
pellet formed was removed with care as it contained the isolated mitochondrial fraction. This 

















Figure 21: Percoll mitochondrial isolation. Percoll ultracentrifugation fractionates mitochondria from 
membranous contaminants. 
 
3.2 BUIRET TEST FOR PROTEIN CONCENTRATION 
 
In order to ensure that equal concentrations of mitochondria were added to the Clarke-
electrode chamber, protein content was measured in each sample (as an indirect indicator of 
mitochondrial concentration) using the Buiret test (155). Briefly, Buiret reagent (appendix 3) 
was added to standard bovine serum albumin protein samples (0.63-10mg/ml) in a ratio of 1 
sample:9 Buiret reagent  and incubated at r om temperature for 20 minutes. Samples were 
then read in a spectrophotometer at 540nm and a concentration-absorbance graph was 
plotted (Figure 22). Mitochondrial samples were assayed for protein content using the Buiret 
test, as described above. Absorbance was read at 540nm and corresponding protein 
















Figure 22:   Buiret concentration-absorbance plot. Standards of bovine serum albumin were plotted. A 
trend line was calculated, and the resulting equation was used for determination of mitochondrial protein 
concentration. 
 
3.3 MITOCHONDRIAL RESPIRATORY ANALYSIS 
 
The Clarke-electrode was set up as depicted in Figure 23: A drop of saturated potassium 
chloride solution (appendix 4) was placed on top of the electrode [1], a roughly 2cm2 square 
of cigarette  paper, followed by equal sized membrane film, were layered on top of this [2] 
and sealed with a rubber O-ring. The outer O-ring was fitted and the space in between 
coated with saturated potassium chloride solution [3]. The electrode was then fitted to the 
chamber [4] and a magnetic stirrer bar added, stirring at a rate of 50 revolutions per minute 
(rpm). To calibrate the Clarke-electrode, sodium theothrioxide was added to approximately 
400μl of potassium buffer (appendix 4) in the chamber in order to deplete the oxygen. The 
machine was zeroed and the chamber thoroughly washed with distilled water before use. 
 















































Figure 23: Clarke-electrode setup. The electrode is assembled as detailed in pictures 1, 2 and 3. The 
electrode is then connected to the oxygraph and housed within the chamber. 
 
Mitochondria were evaluated for oxygen consumption as previously described (156). Briefly, 
mitochondrial samples were diluted to a protein concentration of 0.5mg/ml in potassium 
buffer, and allowed to respire in the chamber at basal levels. In order to stimulate state 2 
respiration, a final concentration of 15nM glutamate was added to the chamber (Figure 24). 
Glutamate stimulates complexes I, III and IV, but not II of the ETC (157) and modest oxygen 
consumption rates are an indication of mitochondrial integrity and health. State 2 respiration 
was allowed to continue for 2 minutes. Thereafter, a final concentration of 0.5mM of ADP 
was added to stimulate the ETC and initiate state 3 respiration (158). This was allowed to 

















Figure 24: Mitochondrial respiration in the Clarke-electrode apparatus. Trace line represents oxygen 
levels within the chamber, and is thus an indirect measurement of oxygen consumption by the 
mitochondria. 
 
Respiratory Control Indices (RCI) were measured by calculating the ratio of state 3 
respiration to state 4 respiration (see Figure 24). RCI values give a good indication of ETC 
coupling and mitochondrial integrity. Any mitochondrial preparation with an RCI value of less 
than 2 was excluded from the study (159). 
 
4: ISOLATED MOUSE CARDIOMYOCYTE MODEL 
 
4.1 ISOLATED CARDIOMYOCYTES 
 
12-14 week old male c57black6 mice were heparinised with 250 IU heparin intraperitoneally 
(160). After 30 minutes, the mice were anaesthetised via an intraperitoneal injection of 
60mg/kg body weight sodium pentobarbital. Once anaesthesia was confirmed via the 
pedoreflex and changes in respiratory parameters (similar to those of the rats mentioned 















blunted 23 gauge cannula in less than 4 minutes. The apparatus used to mount the mouse 
heart was similar to the Langendorff apparatus (Figure 18) with the following exceptions: 
Flow rate was kept constant at 3ml/minute via a pump, functional parameters were not 
measured and hence no balloon was inserted into the ventricle and two independent 
chambers on the apparatus were used to separately house the perfusion buffer and the 
collagenase buffer. Hearts were perfused with oxygenated perfusion buffer (appendix 5) for 
1 minute, followed by perfusion with collagenase buffer (appendix 5) for a further 11 minutes. 
Thereafter, collagenase effluent was collected for 2 minutes in a weigh boat. The heart was 
cut below the cannula and minced finely in the weigh boat with a pair of surgical scissors. 
This suspension was then transferred into a 50ml Falcon tube, attached to a steady supply 
of oxygen gas and shaken in an incubator at 180rpm for 10 minutes (at 37°C). Supernatant 
was then collected in a 15ml Falcon centrifuge tube. 10ml of fresh collagenase buffer was 
added to the remaining pellet and incubated for a further 8 minutes on the incubator/oxygen 
apparatus. Collected supernatant was neutralised with 250μl of foetal bovine serum in the 
interim. After 8 minutes of incubation the supernatant was pooled with the supernatant that 
had already been collected, bringing it to a total volume of roughly 14ml. Cardiomyocytes 
were pelleted via centrifugation at 600 rpm for 3 minutes in a Harrier MSE 18/80 centrifuge 
at room temperature. Supernatant was replaced with 10ml perfusion buffer 2 (appendix 5) 
and the pellet was resuspended with 2 or 3 vigorous taps to the base of the tube.  Calcium 
was then reintroduced via the stepwise manner detailed in appendix 5 to prevent calcium 
shock, over a period of 20 minutes. Cells were left to settle via gravity sedimentation. Gravity 
sedimentation allows for particles in suspension to pellet via the force of gravity. Larger 
particles will travel faster down the tube through the solvent, whilst smaller particles will 
remain in suspension longer, due to the viscosity of the medium (provided by the bovine 
serum albumin). Because viable cardiomyocytes are much larger than dead cardiomyocytes, 
they will pellet prior to the dead cardiomyocytes. It was found that 10 minutes of gravity 
sedimentation resulted in a high yield of viable cells with optimal exclusion of nonviable cells. 
Following sedimentation, the supernatant was carefully removed and the pellet was gently 
resuspended in medium 199 (Appendix 5). Cells were plated onto 30mm 6 well plates 
precoated with 80μl of laminin (Appendix 5) per well. One hour of incubation was then 
allowed for adherence of viable cells to the wells. Wells were then gently washed twice with 
1ml of fresh medium 199. At this point cells were evaluated under the light microscope for 
suitable phenotype and quantification. If found satisfactory (approximately >90% viable 
(Figure 25), and at least 10 000 cells per well), cardiomyocytes were then used for 
















Figure 25: Isolated adult mouse cardiomyocytes. Figure A displays initial crude isolation, and figure B 
shows cardiomyocytes which have been allowed to adhere to laminin coated wells. 
 
4.2 EXPERIMENTAL PROTOCOLS 
 
For cell viability and hypoxia experiments, cardiomyocytes were exposed to 10nM S1P or 
300mg/ml HDL cholesterol for 30 minutes, followed by a 30 minute washout period (Figure 
26). This protocol was adapted from previous work performed in our laboratory or elsewhere 
on cell culture models (161). HDL cholesterol was kindly donated by Dr.Miguel Frias and 
Prof. Richard James (Division of Endocrinology, Diabetology and Nutrition, University 
Hospital, 24, rue Micheli-du-Cr st, CH-1211 Geneva 14, Switzerland). Positive and negative 
controls were also included: CyclosporinA (CsA, 200nM) was administered as a powerful 
inhibitor of mPTP opening (162). Carbonyl Cyanide m-Chloro Phenyl hydrazone (CCCP) 
(10μM) on the other hand, rapidly opens the mPTP and was added at the beginning of 
reperfusion due to its potent cytotoxic effects (163). Normoxic and hypoxic controls were 
also included as baseline references. Following treatment as described above, medium 199 
was removed from plated cardiomyocytes, washed once with either Simulated Ischaemia 
(SI) buffer (appendix 6) or medium 199 and then replaced with 1ml SI Buffer or medium 199. 
Cardiomyocytes were exposed to 2 hours total hypoxia, a time course derived from the 
literature, with a degree of optimisation (164),(165),(166) using a Gentronics CO2 and O2 
Gas Controller (a sealed, temperature and gas controlled incubator). O2 levels were 
maintained at 1%, with upper and lower limits of 0.5% and 1.5%. CO2 levels were similarly 
maintained at 5% with upper and lower limits of 6% and 4%, respectively. Temperature was 
kept constant at 37°C.  
For western blotting analysis, proteins were extracted after 7 minutes of drug treatment, as 

















Figure 26: Experimental protocols for isolated mouse cardiomyocytes. Arrows indicate time of 
mitochondrial protein isolation for western blot analysis (7 minutes since start of treatment). CsA = 
Cyclosporin A. CCCP= Carbonyl Cyanide m-Chloro Phenyl hydrazine.  
 
4.3 TRYPAN BLUE STAINING 
 
Directly after hypoxia, cells were reoxygenated for 20 minutes with no change in medium. 
Cells were then loaded with 0.04% Trypan Blue (100μl of 0.4% Trypan Blue solution was 















microscope at 40x magnification. Trypan Blue is impermeable to cell membranes, and thus 
may only enter the cell if membrane integrity has been compromised (167). Thus dead cells 
(both apoptotic and necrotic) stain blue, whereas live cells remain unstained. Cell death 
could also be ascertained via morphological changes. Dead cells were round, while viable 
cells remained rod shaped. Trypan Blue was added directly to the well, and 4 randomly 
selected focal points, or a minimum of 100 cells each, were analysed. 
 
5: ANALYSIS OF MPTP OPENING 
 
mPTP opening was measured in isolated mouse cardiomyocytes subjected to hypoxia and 
pretreated with or without S1P or HDL cholesterol. mPTP opening was measured using the 
dye TetraMethylRhodamine Methylester (TMRM) (Invitrogen). TMRM is a lipophilic cation 
that accumulates in the mitochondrial inner membrane and matrix due to its charge and 
relative solubility in these regions (168). Importantly, TMRM has a low binding coefficient to 
proteins and hence will only enter mitochondria relative to their membrane potential, and will 
leave just as freely if the membrane depolarises. TMRM fluorescence was measured using 
both fluorescent microscopy methods and flow cytometry methods.  
 
5.1. EXPERIMENTAL PROTOCOLS 
 
Following hypoxia, cells were removed from the hypoxic chamber, and all cells were 
incubated with TMRM for 10 minutes (169). After incubation with TMRM, medium was 
replaced with fresh medium 199 for all cardiomyocytes and incubated for a further 10 
minutes. For fluorescent microscopy, four focal points, or at least 100 cells, were 
immediately photographed. For flow cytometry, cardiomyocytes were lifted from the wells 
using a cell scraper, and transferred into a 10ml Falcon tube for flow cytometry analysis. 10 
000 events were counted.  Some researchers argue strongly for the treatment of 
cardiomyocytes with digitonin in order to allow for entry of TMRM into the cells (170), 
however this is not necessary, as evidenced by the obvious incorporation of TMRM into the 
cells when analysed using a fluorescent microscope (Figure 38). There were also concerns 
that digitonin treatment may adversely affect the membrane potential of the mitochondria, 
and hence it was omitted. Trypsin was not used to lift the cells from the wells because of 
similar fears, and so the cell scraping method was used instead. 
 
5.2 FLUORESCENT MICROSCOPY 
 
After 10 minutes of incubation in medium 199, cardiomyocytes were photographed using a 
green lit fluorescent microscope (Camera SPOT RT Colour 2.2.1. Images were taken using 
a Nikon Eclipse TE200 camera and captured with Spot Advanced imaging software). 
Fluorescent levels were then analysed using planimetric methods using ImageJ software. 
Because absolute fluorescent levels vary depending on cell number, microscopy focus, age 















normoxic cells analysed on the day of the experiment. The nature of TMRM is such that 
fluorescence levels are unlikely to ever dip below 50% of their baseline because the dye 
accumulates in the mitochondria based on proton gradients. With complete mPTP opening, 
this gradient is lost and the dye will passively diffuse until it reaches equilibrium with the 
cytosol and extracellular fluid. In addition to this, dead cells fluoresce at much higher levels 
than healthy cells (Figure 27) and thus are excluded from analysis by their morphological 
features. 
 
Figure 27: TMRM Fluorescence of isolated mouse cardiomyocytes. A dead cell at left, clearly identifiable 
by its round morphology, fluoresces at much higher levels than a healthy cell at right. 
 
5.3 FLOW CYTOMETRY 
 
Because The Hatter Cardiovascular Research Institute at the University of Cape Town does 
not have a fluorescent microscope, and the preliminary fluorescent microscopy studies were 
performed at The Hatter Institute at University College London, a subsection of this thesis 
consisted of set up of a flow cytometry method of TMRM measurement. Analysis of 
cardiomyocytes with a flow cytometer is well established (171), but was never used following 
a hypoxic stress which represented a unique set of challenges. Similarly, mPTP opening 
analysis has been performed using a flow cytometer in fibroblasts (172), but has not been 
applied in isolated cardiomyocytes. As such, this is was a novel technique that has not been 
detailed in the literature. The advantages of using a flow cytometer are that it allows for 
analysis of a larger numbers of cells, strengthening the statistical confidence of the results. It 
also objectively analyses the cells, unlike the more traditional methods of confocal or 
fluorescent microscopy analysis of mPTP opening in cardiomyocytes (173). It is however an 
expensive method as compared to fluorescent microscopy, but of equitable expense as 
compared to confocal microscopy. As such, significant calibration and optimisation of this 
methodology was required. Once the settings for the flow cytometer had been optimised, 
they remained constant throughout all experiments.  
5.3.1 Calibration and Optimisation 
The flow cytometer uses a laser to analyse individual cell characteristics. It can measure 
three aspects of the cell: Cell size (forward scatter), cell granularity (side scatter), and 















autofluorescence of the cell, or it can measure antibody-linked or dye treated fluorescence. 
In this case, the dye TMRM was used as a measurement of mPTP opening. TMRM’s 
absorption and emission spectra are detailed in Figure 28. Based on its absorption profile, 
an excitation laser of 488nm was used to stimulate the dye (which is the standard laser fitted 
to a FacsCalibur flow cytometer) (174). 
 
 
Figure 28: Absorption/emission spectra of TMRM. Absorption is conveyed by the dotted green line, while 
the emission spectrum is portrayed by the solid green line. The blue line depicts a 488nm stimulus, 
equivalent to the 488nm laser equipped on the flow cytometer (175). 
 
The flow cytometer allows for modification of amplification of forward scatter (FSC), side 
scatter (SSC) and the FL-2 channel in order to accommodate variations in size and 
granularity between different cell types, and fluorescent intensities of different dyes. As a 
flow cytometry model of TMRM fluorescence in isolated mouse cardiomyocytes is a novel 
model, significant optimisation of all these settings was required (176) and the optimal 
TMRM dye concentration needed to be established (177).  
In order to optimise the flow cytometer, during the gravity sedimentation component of 
cardiomyocyte isolation, the pellet, which contained majority rod shaped live cells was 
immediately analysed with no fluorescent dye treatment as a control of viable cells. It also 
allowed for the detection of any autofluorescence that may have been in play. Concurrently, 
the supernatant from the gravity sedimentation was reserved and spun at 1000g for 3 
minutes. This resulted in a pellet of majority rod shaped, dead cells. These were also 
analysed on the flow cytometer as a control for dead cells. Furthermore, settings were 
optimised so as to prevent as many events as possible from being read off scale, as gating 
of populations following acquisition can be done at any stage. However, if the samples are 
recorded off scale, this cannot be remedied post-acquisition. 
Fluorescent microscopy techniques use 200nM of TMRM, however flow cytometry 
techniques use a lower concentration of 20nM, most likely due to the intensity of the laser 
excitation. Initially a concentration of 200nM TMRM was used so as to deviate as little as 
possible from the fluorescent microscopy technique, however this proved to be unfeasible 
and resulted in too strong a signal for the FL-2 channel to detect. As such the TMRM 
concentration was reduced to 20nM and the FL-2 channel adjusted. The final amplification 

















Table 5: Flow cytometry settings for mPTP opening analysis. FSC= Forward Scatter, SSC=Side Scatter. 
Derived from (177), (178), (179) and (174) with significant optimisation. V = Voltage, Amp=Amplifiers 
 
5.3.2 Gating 
The flow cytometer records all fragments that pass through its laser as events, and it cannot 
distinguish between viable cells, cellular detritus and other contaminants. As such, it is 
necessary to exclude these components from the analysis via gating of populations. Figure 
29 shows typical TMRM fluorescence histograms for normoxic and hypoxic cells, with their 

















Figure 29: FL-2 fluorescent histograms and FSC and SSC plots. A. Normoxic cells B. Hypoxic cells. FSC 
= Forward scatter, SSC = Side scatter 
 
Two clear populations are visible in the FSC and SSC plots, as well as a third lower 
population. The FL-2 histograms also show a clear decrease in fluorescence in the hypoxic 
group.  When cells with virtually no TMRM fluorescence (0-10 units) are gated, they occupy 
the left population of the FSC and SSC plots (Figure 30), whereas the higher fluorescing 
cells occupy the right population (gating not shown). Due to the variability in size of individual 
cardiomyocytes FSC is not a good indication of cell viability (180), whereas SSC does 
remain a good indication. Furthermore, cellular detritus and other contaminants will have a 
very low FSC and SSC value and no fluorescence, and are evidenced by the third 
population found in the very lower left hand corner of the scatter plot (which is also retained 
when gated for low fluorescence). This is further supported by anecdotal evidence, where  
these low fluorescent events only occur right at the end of a run when sucking up 
contaminants floating on the surface of the sample in the test tube, if at all. As such, gating 


















Figure 30: Gated population (R2) of events registering little to no fluorescence.  
 
6: WESTERN BLOTTING 
 
Western blot analysis was used to quantify mitochondrial protein levels, specifically total 
STAT-3 and its phosphorylated isoform at Serine 727 (pSTATSer), following HDL cholesterol 
or S1P treatment. All samples were also probed for Voltage Dependent Anion Channel 1 
(VDAC), as a normalisation molecule to control for protein concentration and loading 
differences.  
 
6.1 PROTEIN PREPARATION 
 
Cardiomyocytes were isolated as previously described (section 4.1). Once isolated, the 
cardiomyocytes were resuspended in phosphate buffered saline (PBS), and treated with 
either 10nM S1P or 300mg/ml HDL cholesterol for 7 minutes at 37°C. Thereafter, a 
mitochondrial isolation kit (Sigma) for profiling cultured cells was used to isolate 
mitochondria. The procedure entailed homogenization with 10 strokes of a glass dounce 
homogenizer, incubation in supplied buffers at 4°C and various centrifugations as per the 
manufacturer’s instructions. 
In order to ensure that equal amounts of protein (60μg) were loaded into each well, a Buiret 
protein concentration test was performed as detailed in section 3.2. Corrected 















amount of loading buffer (see Appendix 7) to a final volume of 20μl. Unlike typical western 
blotting protocols, mitochondrial fractions were not boiled, as this can result in dimerisation 
of the proteins (181). 
 
6.2 GEL ELECTROPHORESIS 
 
Gel electrophoresis 1.5mm glass plates were cleaned with 70% ethanol before being set up 
as per manufacturer’s instructions (Biorad) (Figure 31). The system was checked with water 
for a watertight seal prior to pouring of the gel. Separating gel (see Appendix 7) was then 
added in-between the plates such that it ended approximately 1cm below the loading wells 
(as predetermined using the well-forming combs). A thin film of 70% ethanol was layered on 
the top to ensure a level line, remove potential air bubbles and to encourage setting of the 
gel by isolating it from atmospheric oxygen. Once the separating gel set, the ethanol was 
removed with blotting paper and the stacking gel (see Appendix 7) was added to the brim of 
the chamber. Any bubbles formed on the top were removed, using a needle and syringe, 

















Figure 31: Setup of Gel electrophoresis plates. A 15mm backing plate is covered with a glass front plate 
and sealed into place with a green clamp. This is then clamped onto a docking station to ensure the 
plates remain level and secure. A grey sponge base ensures water tightness of the system. 
 
Once the stacking gel was set, the combs were carefully removed and the gel plates were 
loaded into the running apparatus. The running apparatus was transferred into a running 
chamber. The chamber was flooded with 1x running buffer, prepared from a 10x stock 
solution (appendix 7). Each individual well was washed out using a syringe and fine needle 
prior to protein loading to remove any gel debris inside the well. Protein preparations were 
then loaded. 4µl of a molecular marker (PeqGold Prestained Protein Marker IV from 


















6.3 MEMBRANE TRANSFER 
 
Amersham Hybond-P membranes (GE Healthcare) were washed for 5 minutes in methanol, 
followed by 2 minutes in distilled water, and finally 15 minutes in transfer buffer (appendix 7). 
The gel was removed from the glass plates and prepared via the removal of the stacking gel. 
Immunoblot transfer apparatus was then set up as detailed below (Figure 32). This 
apparatus was immersed in transfer buffer during the set up process, ensuring any air 
bubbles between the gel and membrane were excluded. The immunoblot transfer apparatus 
was then inserted into a transfer chamber, along with an ice pack to prevent overheating 
during the transfer process. This was filled with transfer buffer and allowed to run at 0.02A 
overnight in a 4°C fridge. 
 
 
Figure 32:  A: Set up of transfer system for western blot analysis. It is important that the anode facing 
part of the transfer case (usually black) is at the bottom as the proteins migrate from the anode (-) to the 
cathode (+) lifting off the gel and transiently passing onto the membrane. The proteins adhere to the 
membrane and lose their charge, which stops the transfer process.  B: Side view of set up of Transfer 
system. PAGE = Polyacrylamide Gel Electrophoresis  
 
6.4 PONCEAU STAINING 
 
After transfer, the membrane was washed in methanol for 30 seconds, and allowed to dry 
completely. Membranes were then washed with Ponceau stain briefly, rinsed with water, 
sandwiched between two transparencies and digitally scanned (Figure 33). These scans 
were captured to confirm the presence of protein and equal protein loading amongst the 
samples. Ponceau stain was removed by washing three times in TBS-T (appendix 7), each 





















Membranes were blocked with a 5% milk solution (appendix 7) for 2 hours to prevent non-
specific binding of antibodies to the membrane. They were then washed three times with 
TBS-T, each for 5 minutes. Thereafter they were exposed to one of 2 primary antibodies: 
tSTAT or pSTATSer (appendix 7) overnight at 4°C on a rotating stand. Another washing step 
of 3 washes in TBS-T for 5 minutes each was performed, before being exposed to the 
secondary antibody (appendix 7) for 1 hour on a shaking tray. A final washing step of 3 




Membranes were incubated simultaneously in 2mls each of ECL developing reagents 1 and 
2 (GE Healthcare) for 2 minutes. Membranes were then analyzed using the GENE Genome 
image capturing system (Syngene). A light image was also captured for the molecular weight 
marker, as it was not luminescent. A composite image was created in order to identify the 




Following development, all membranes were washed twice for 5 minutes in dH2O. 
Membranes were then stripped with 0.2M NaOH for 5 minutes on a shaker tray. Finally, they 
were further washed twice for another 5 minutes each with dH2O, before being processed for 
VDAC development, following the same protocol as listed in sections 6.5 and 6.6 above, with 





















Unless stated in the text, all reagents were supplied by Sigma-Aldrich. 
 
7.2 ANALYSIS SOFTWARE 
 
For infarct size analysis, heart sections were placed between two glass plates and scanned 
into the computer. Images were then printed out and a stylus was used to trace the 
perimeter of the heart, the area at risk and the infarcted tissue. This data was then analysed 
using Planimetry+ software. 
For flow cytometry analysis, Gating and fluorescence levels were analysed using FlowJo 
7.6. Mean fluorescence intensity was calculated, and normalised to the normoxic levels.  
For  fluorescent microscopy and western blot analysis, densitometry was performed using 
ImageJ version 1.44p. 
  
7.3 STATISTICAL ANALYSIS 
 
All statistical analysis was performed using Graphad Instat v3.01. All data is expressed as 
mean ± the Standard Error of the Mean (SEM).  
Statistical significance between 2 groups (infarct size analysis, functional recovery data and 
RCI values) was determined by an unpaired, two-tailed t-test. 
Statistical significance between more than 2 groups was determined by a one way analysis 
of variance (ANOVA), followed by a Student Newman-Keuls post hoc test, for isolated 
cardiomyocytes (flow cytometry, cell survival data and western blotting). 
 





























Chapter 4: Results 
 
1: S1P PROTECTS AGAINST ISCHAEMIA/REPERFUSION INJURY IN 
THE ISOLATED RAT HEART 
 
1.1 EFFECT OF S1P ON FUNCTIONAL PARAMETERS. 
 
Preischemic functional parameters (Table 6) for both the ischemic controls (IC) and the S1P 
treated hearts met all the inclusion criteria outlined in section 2.1 of the methods chapter. 
Postischemic values of the IC group displayed a significantly diminished LVDP 
(86.0±7.0mmHg preischaemia vs. 46.0±8.0mmHg postichemia, p<0.05). Coronary flow rate 
was also significantly decreased from 10.8±1.4 ml/minute to 7.8±1.9 ml/minute (p<0.05). 
These findings were consistent with those described in the literature, validating our model of 
regional ischaemia-reperfusion injury (182),(183). Pretreatment with 10nM S1P rescued 
neither LVDP nor coronary flow rate. No significant decrease following ischaemia was 
observed in heart rate for either IC or S1P groups 
 
Time point LVDP Coronary Flow Rate Heart Rate 
  IC S1P IC S1P IC S1P 
Preischemic 86±7 83±5 10.8±1.4 9.7±0.9 287±18 276±20 
Reperfusion 5 min 69±8 71±7 11.2±1.7 9.8±0.8 270±14 288±42 
Reperfusion 30 min 61±6 61±8 9.8±1.8 7.0±0.8 287±11 260±38 
Reperfusion 120 min 46±8 45±7 7.8±1.9 5.9±0.8 293±11 268±28 
Table 6: Summary of functional recovery data. No significant differences were found between the IC or 
S1P groups at any time point. 
 
1.2 EFFECT OF S1P ON INFARCT SIZE  
 
Isolated rat hearts subjected to 30 minutes of regional ischaemia and 2 hours of reperfusion 
(IC) had an infarct size of 25.8±3.1% of the area at risk (Figure 34). Pretreatment with S1P 
significantly decreased infarct size to 4.6±1.4% of the area at risk (p<0.05 vs. IC). Our data 
confirmed previous data reported in the literature (184) on the cardioprotective effect of S1P. 
















Figure 34: Infarct size of isolated rat hearts subjected to regional ischaemia-reperfusion. Pretreatment 
with S1P (10nM) reduced infarct size from 25.8±3.1% to 4.6±1.4% of the area at risk. (*p<0.05 vs. IC, n=6 
for all groups). IC = Ischemic Control. 
 
1.3 EFFECT OF S1P ON RESPIRATORY PARAMETERS  
 
Untreated isolated rat heart mitochondria measured RCI values of 4.2±0.5 Arbitrary Units 
(AU), consistent with those cited for rat heart mitochondria in the literature (185),(159),(186) 
(Figure 35). Hearts treated with S1P prior to mitochondrial isolation, displayed significantly 













































Figure 35: Respiratory Control Index (RCI) values of isolated rat mitochondria. S1P (10nM) improves RCI 
values (*p<0.05 vs. Untreated, n=4 for all groups). 
 
2: S1P AND HDL CHOLESTEROL PROTECT AGAINST HYPOXIA IN 
ISOLATED WILDTYPE MOUSE CARDIOMYOCYTES 
 
2.1 EFFECT OF S1P AND HDL CHOLESTEROL ON CELL VIABILITY 
 
Normoxic cardiomyocytes had a mean viability of 84.4±1.6%, indicating that approximately 
15% of cardiomyocytes did not survive the isolation and plating process (Figure 36). 
Exposure to 2 hours hypoxia reduced cardiomyocyte survival to 62.7±1.8% (p<0.05 vs. 















































Figure 36: Effect of S1P on cell viability in isolated wildtype cardiomyocytes subjected to 2 hours of 
hypoxia. S1P (10nM) improves cell survival. (*p<0.05 vs. Hypoxia, n=4 for all groups). 
 
Similarly for the HDL cholesterol experiments, untreated cardiomyocytes had a mean 
survival of 84.3±1.5% (indicating roughly 15% of cardiomyocytes did not survive the isolation 
and plating process) (Figure 37). Exposure to 2 hours of hypoxia significantly reduced cell 
viability to 59.6±2.5%. Administration of 10μM CCCP to normoxic cells (a potent 
mitochondrial membrane depolarizer) also resulted in a significant reduction in cell viability to 
64.3±3.9%. Administration of HDL cholesterol prior to exposure to hypoxia abrogated the 












































Figure 37: Effect of HDL cholesterol on cell viability in isolated cardiomyocytes subjected to 2 hours of 
hypoxia. HDL cholesterol (300mg/ml) improved cell survival. (*p<0.05 vs. Hypoxia. n=8 for all groups, 
except CCCP which had an n=4). CCCP=Carbonyl Cyanide m-Chloro Phenyl hydrazone (10μM). 
 
2.2 EFFECT OF S1P AND HDL CHOLESTEROL ON MPTP OPENING  
 
TMRM fluorescence was measured using two techniques: flow cytometry and fluorescent 
microscopy in the S1P group, while the HDL cholesterol group was only measured using 
flow cytometry.  
In the fluorescent microscopy model, isolated mouse cardiomyocytes subjected to 2 hours 
hypoxia displayed a decrease in fluorescence to 77.8±2.0% of the normoxic controls (p<0.05 
vs. Normoxia) (Figure 38). Cardiomyocytes treated with CsA had restored levels of 
fluorescence (94.3±1.0%), indicating inhibition of opening of the mPTP and validating the 
fluorescence microscopy model. Pretreatment of cells with 10nM S1P restored fluorescence 













































Figure 38: Effect of S1P on TMRM fluorescence in isolated cardiomyocytes using a fluorescent 
microscope. Fluorescence is given as arbitrary fluorescent intensity units (AFU). Both S1P (10nM) and 
CsA (200nM) restored fluorescent levels to normoxic values. (*p<0.05 vs. Hypoxia. n=6 for all groups). 
CsA= Cyclosporin A. 
 
In the flow cytometry model, hypoxic cardiomyocytes experienced a decrease in 
fluorescence to 83.7±6.3% of the normoxic control level (p<0.05 vs. normoxia) (Figure 39).  














































95.5±4.3% of the normoxic control levels. These results for hypoxic and S1P treated groups 
were similar to the fluorescent microscopy results, which validated the use of the flow 
cytometry model for fluorescence analysis of TMRM. 
 
 
Figure 39: Effect of S1P on TMRM fluorescence in cardiomyocytes using a flow cytometer. Pretreatment 
with S1P (10nM) prior to hypoxia restored fluorescence levels to normoxic values. (*p<0.05 vs. Hypoxia. 
n=9 for all groups). 
 
For the HDL cholesterol experiments, hypoxia reduced fluorescence intensity to 76.3±6.0% 
of the normoxic cardiomyocyte’s value (p<0.05 vs. normoxia), indicating an opening of the 
mPTP (Figure 40). Similar to its effect on cell viability, pretreatment with HDL cholesterol 
significantly prevented fluorescence intensity loss (88.4±11.0%), indicating retention of 
membrane potential. Treatment with CCCP had the expected result of depolarising 
mitochondrial membranes, resulting in a substantial decrease in TMRM fluorescent levels; 













































Figure 40: Effect of HDL cholesterol on TMRM fluorescence levels in cardiomyocytes exposed to hypoxia 
using a flow cytometry. HDL cholesterol (300mg/ml) restored fluorescent levels to normoxic values. 
Treatment with CCCP alone reduced levels to 56.5+-14.0% of normoxic values. (*p<0.05 vs. Hypoxia. 
#p<0.05 vs. Normoxia. n=6 for all groups). CCCP= Carbonyl Cyanide m-Chloro Phenyl hydrazone (10μM). 
 
2.3 EFFECT OF S1P AND HDL CHOLESTEROL ON MITOCHONDRIAL STAT-3 
LEVELS  
 
Mitochondria were isolated from the cardiomyocytes of wildtype mice, following which they 
were probed for total STAT-3 levels, or phosphorylated STAT-3 (serine) levels. Blots were 
then stripped and re-probed for VDAC. All results were normalised to their respective VDAC 
levels. 
2.3.1 Effect of S1P and HDL cholesterol on total STAT-3 levels  
Untreated cardiomyocytes had total STAT (tSTAT) levels of 0.38±0.04 Arbitrary Units (AU) 
(Figure 41). Neither S1P (0.43±0.05 AU) nor HDL cholesterol (0.46±0.05 AU) pretreatment 

















































Figure 41: Effect of HDL cholesterol (300mg/ml) or S1P (10nM) on total STAT-3 (tSTAT) levels in 
mitochondria. Data are normalised to VDAC levels, and expressed as arbitrary units (AU). Neither S1P 
nor HDL cholesterol increased tSTAT levels in the mitochondria (n=4). 
 
2.3.2 Effect of S1P and HDL cholesterol on pSTATSer levels  
Untreated cardiomyocytes had phosphorylated levels of STAT-3 (serine) of 0.57±0.05 AU 
(Figure 42). Pretreatment with S1P significantly increased these levels to 1.13±0.25 AU 
(p<0.05 vs. untreated). However, HDL cholesterol pretreatment did not increase 















































Figure 42: Effect of HDL cholesterol (300mg/ml) or S1P (10nM) on serine phosphorylated STAT-3 
(pSTATSer) levels in mitochondria. Data are normalised to VDAC levels, and expressed as arbitrary units 
(AU). S1P pretreatment increased levels of pSTATSer in the mitochondria (*p<0.05 vs. Untreated).HDL 
cholesterol had no effect (n=4). 
 
3: S1P AND HDL CHOLESTEROL FAIL TO PROTECT AGAINST 
HYPOXIA IN ISOLATED STAT-3 KO MOUSE CARDIOMYOCYTES 
 
The relationship between S1P, HDL cholesterol and STAT-3 signalling to the mitochondria 
was investigated using transgenic STAT-3 KO mice subjected to hypoxia. 
 
3.1 EFFECT OF S1P AND HDL CHOLESTEROL ON CELL VIABILITY 
 
Normoxic cardiomyocytes had a mean viability of 78.7±3.3% survival, indicating that 
approximately 20% of cells did not survive the isolation process (Figure 43). Two hours of 
hypoxia decreased cell viability to 60.2±4.8 (p<0.05 vs. normoxia). Pretreatment with S1P 
conferred no protection against hypoxia, with a cell survival of 58.3±3.8% (not significant vs. 
hypoxia). HDL cholesterol pretreatment also did not improve cell viability in isolated 




















































Figure 43: HDL Cholesterol and S1P have no cardioprotective effect in STAT-3 KO mice. Neither HDL 
cholesterol (300mg/ml) nor S1P (10nM) enhanced cell survival following 2 hours exposure to hypoxia 
(*p<0.05 vs. Normoxia. n=6 for all groups).  
 
3.2 EFFECT OF S1P AND HDL CHOLESTEROL ON MPTP OPENING  
 
Relative to fluorescence levels of normoxic controls, 2 hours of hypoxia reduced 
fluorescence to 80.7±11.9% (p<0.05 vs. normoxia) (Figure 44). Pretreatment with S1P did 
not restore fluorescence (73.8±6% of the normoxic control, not statistically different from the 
hypoxic group). Similarly, there was no significant difference in fluorescence levels between 
the hypoxic and HDL cholesterol group, which had a reduced fluorescence of 72.8%±7.7 












































Figure 44: Effect of HDL Cholesterol and S1P on mPTP opening in isolated cardiomyocytes from STAT-3 











































































Chapter 5: Discussion 
 
1: SUMMARY OF RESULTS 
 
Our data demonstrates that HDL cholesterol and its component S1P confer cardioprotection 
against ischaemia via the inhibition of opening of the mPTP. In brief, both native HDL 
cholesterol and S1P improved cardiomyocyte viability and inhibited opening of the mPTP. 
Furthermore, experiments repeated in STAT-3 deficient cardiomyocytes suggest that the 
effect of HDL cholesterol and S1P is mediated via the activity of STAT-3. This suggests a 
role of the SAFE pathway in HDL cholesterol and S1P cardioprotection. A summary of our 
experimental results is presented below. 
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IN MITOCHONDRIA  
 
   





Table 7: Summary of Results. Green arrows indicate positive cardioprotective changes relative to the 
hypoxic control, whilst red arrows indicate negative changes relative to the normoxic control. 
 
 Isolated rat hearts treated with 10nM S1P prior to 30 minutes of regional ischaemia and 
120 minutes of reperfusion displayed a significant decrease in infarct size. S1P did not 
improve functional parameters. Mitochondria isolated from rat hearts prior to the 















S1P. This suggests a role for the conservation of mitochondrial function in the 
cardioprotective effect observed with S1P.  
 Treatment of isolated mouse cardiomyocytes with either S1P (10nM) or HDL cholesterol 
(300mg/ml) conferred marked cytoprotection against 2 hours of hypoxic stress. 
Furthermore, both treatments reduced opening of the mPTP.  
 In contrast, neither S1P nor HDL cholesterol improved cell viability in STAT-3 KO mice, 
nor could the opening of the mPTP be inhibited with either treatment. 
 S1P increased phosphorylation of STAT-3 at its serine residue within the mitochondria, 
but did not increase total STAT-3 levels. HDL cholesterol had no effect on STAT-3 levels 
or phosphorylation. 
 
2: CARDIOPROTECTIVE EFFECTS OF S1P AND HDL CHOLESTEROL 
 
Using isolated perfused rat hearts and isolated adult mouse cardiomyocytes, our data 





The isolated rat heart ischaemia-reperfusion model showed significant reduction in infarct 
size following treatment with S1P (Figure 34). Infarct sizes of control hearts previously 
reported in the literature average approximately 35% (26). Our infarcts are smaller, 
and this could be attributed to the severity of the occlusion, which depends on how 
high up the occlusion is made on the c ronary artery. S1P did not improve functional 
recovery. Previous studies exploring the cardioprotective effect of various drugs in this 
model have not reported a change in functional recovery either (187). Treatment with S1P 
also protected isolated adult mouse cardiomyocytes against a hypoxic stress (Figure 36). 
This is the first time S1P has been administered to adult cardiomyocytes in a hypoxia model. 
Karliner et al. have administered S1P to neonatal rat cardiomyocytes and shown a protective 
effect against hypoxia, however the concentrations of S1P used were much higher (188). 
 
The cardioprotective concentrations for S1P cited in the literature range from 10nM (189) to 
10μM (188). Our choice of a low concentration of S1P was justified by the physiological 
concentrations of unbound S1P in the plasma, approximately 10nM (190). Furthermore, high 
concentrations of S1P have been associated with coronary vasoconstriction, bradycardia 
and decreased blood pressure (191),(192). Therefore, the use of a lower concentration of 
S1P is also justified in limiting the potential side effects of administration of S1P. 
 
2.2 HDL CHOLESTEROL 
 
HDL cholesterol protected isolated adult mouse cardiomyocytes from hypoxic cell death 
(Figure 37). HDL cholesterol has previously been shown to protect cardiomyocytes against 
doxorubicin induced apoptosis at similar concentrations (193). Our results are the first to 
















The degree of cardioprotection observed with HDL cholesterol was similar to that observed 
with S1P treatment. Our data suggest that S1P may be regulating the cardioprotective effect 
of HDL cholesterol. Many experimental studies have attributed the cardioprotection of HDL 
cholesterol to its apoA content, as the use of reconstituted HDL cholesterol has been shown 
to protect against ischaemia-reperfusion injury (194),(195). Reconstituted HDL cholesterol is 
composed of palmitoyloleoyl phosphatidylcholine, cholesterol and ApoA, and does not 
contain S1P (196). Our data strongly suggests that addition of S1P in reconstituted HDL 
cholesterol may enhance the protection against ischaemia-reperfusion injury. In fact, 
preliminary work done in our laboratory using an isolated mouse heart model demonstrated 
that reconstituted HDL cholesterol enriched with S1P is more cardioprotective than 
reconstituted HDL cholesterol containing ApoA alone (197). The use of reconstituted HDL 
cholesterol containing both ApoA and S1P, rather than S1P unbound to HDL cholesterol, 
may be a more physiological, and therefore safer, option in delivering S1P to patients. 
Recently, the presence of apolipoprotein M has been characterised in HDL cholesterol, and 
it is suggested that apolipoprotein M controls the bioavailability of S1P bound to HDL 
cholesterol (198). However, data from our group showing that reconstituted HDL cholesterol 
containing S1P alone, and no apolipoproteins, can confer cardioprotection. This suggests 
that S1P bound to HDL cholesterol is cardioprotective independent of the apolipoproteins in 
our setting (199). 
 
2.3 ROLE OF THE SAFE PATHWAY 
 
2.3.1 Changes in mitochondrial STAT-3 
Recent literature suggests that STAT-3 phosphorylation is critical to mediate 
cardioprotection (71). However, it is not clear whether phosphorylation of STAT-3 occurs 
inside or outside the mitochondria. Our data showed no significant differences in levels of 
total STAT-3 protein in mitochondria isolated from wildtype mouse cardiomyocytes following 
treatment with either S1P or HDL cholesterol (Figure 41). This result suggests that there is 
no translocation of STAT-3 from the cytosol into the mitochondria, and STAT-3 
phosphorylation may instead result from a phosphorylation cascade happening within the 
mitochondria. Surprisingly, phosphorylation of STAT-3 at the serine residue was increased in 
the mitochondria following treatment with S1P, but not with HDL cholesterol (Figure 42). 
There are various explanations for this apparent discrepancy.  
Firstly, the time selected for analysing STAT-3 phosphorylation may not have been optimal. 
Here, mitochondria were harvested 7 minutes after treatment. Our laboratory has 
demonstrated a transient phosphorylation of STAT-3 signalling in mitochondria following 
treatment with S1P (200). In an isolated mouse heart model, protein extraction following 7 
minutes of S1P treatment resulted in an increase in phosphorylated STAT-3, which 
disappeared at 15 minutes. It is reasonable to assume that the time point selected in our 
isolated cardiomyocyte model may not have been the optimal time point to detect 
phosphorylated STAT-3.  
Secondly, unbound S1P might exert its effect quicker than the S1P bound to the HDL 
cholesterol molecule.  
Thirdly, the phosphorylation of STAT-3 may not be required for the protection. Recent 
studies have demonstrated a pathophysiological role for unphosphorylated STAT-3 and this 















Lastly, there is also the possibility that the protective effect of STAT-3 is not the result of its 
translocation into the mitochondria. STAT-3 may instead translocate to the nucleus and 
subsequently activate unknown factors which influence the mitochondria. Alternatively, it 
may be part of the cytosolic signalling to the mitochondria, possibly as part of a signalosome 
as described by (202), and hence only gets as far as the outer mitochondrial membrane, but 
not get incorporated into the mitochondria. However, if HDL cholesterol is acting via a 
pathway independent of S1P, it would argue against our hypothesis that S1P is the active 
cardioprotective component of HDL cholesterol. 
2.3.2 Cardioprotection in STAT-3 KO mice 
Our data (Figure 43) clearly demonstrate a loss of S1P and HDL cholesterol cardioprotection 
in STAT-3 KO cardiomyocytes. Although S1P and HDL cholesterol have already been 
reported to activate STAT-3 (199),(203), our data demonstrate for the first time, to our 
knowledge, that activation of STAT-3 is required for S1P and HDL cholesterol induced 
cardioprotection against hypoxia.  This suggests that STAT-3, a component of the SAFE 
pathway, is a crucial regulator of HDL cholesterol and S1P induced cardioprotection.  
 
3: EFFECT OF S1P AND HDL CHOLESTEROL ON MITOCHONDRIAL 
FUNCTION 
 
3.1 RESPIRATORY CONTROL INDICES 
 
Treatment with S1P in isolated rat hearts resulted in a significant improvement of the RCI 
values of mitochondria (Figure 35). It is important to note that these are baseline levels, and 
not following exposure to any form of ischaemia. The validity of the treatment protocol and 
S1P concentration used was confirmed by those hearts which were exposed to ischaemia 
displaying a significant decrease in infarct size. There are two explanations for the difference 
in RCI values observed.  
Firstly, there is evidence that S1P is present within the mitochondria and that it interacts 
directly with complex IV of the ETC, positively modulating respiration (204). Whether 
exogenous treatment with S1P increases mitochondrial levels of S1P remains unknown, but 
it is possible that in our model, administration of exogenous S1P increased levels of S1P in 
the mitochondria, and therefore improved respiratory function. 
Alternatively, Percoll isolation may produce mild stress within the mitochondria, leading to 
mPTP opening and potential uncoupling of the ETC. S1P inhibits mPTP opening as 
demonstrated in this thesis, and this may preserve the respiratory function of the isolated 
mitochondria. 
  
3.2 INHIBITION OF THE MPTP 
 
Both S1P and HDL cholesterol pretreatment resulted in significant inhibition of mPTP 















separate models (albeit using the same fluorescent dye), therefore strengthening the 
evidence for S1P and HDL cholesterols effect on mPTP opening. The validity of the flow 
cytometer model in the analysis of TMRM fluorescence was confirmed using the fluorescent 
microscopy technique. The reduction in fluorescence in the hypoxic groups may seem 
modest, and the subsequent restoration by S1P and HDL cholesterol even more so, but it is 
important to bear in mind the limitations of the technique.  
Our data demonstrate a role for HDL cholesterol and S1P on mPTP opening, and this is 
supported by the recent discovery that a knock-out model of sphingosine kinase 2 within the 
mitochondria is more susceptible to mPTP opening (205). 
 
3.3 MPTP INHIBITION IN STAT-3 KO MICE 
 
There was no inhibition of the mPTP by either HDL cholesterol or S1P in the STAT-3 KO 
cardiomyocytes (Figure 44). Combined with the cell viability data, our experiments suggest 
that HDL cholesterol and S1P are exerting their cardioprotective effects through the 
inhibition of mPTP opening, which is dependent on STAT-3 activation. 
 
4: CLINICAL RELEVANCE 
 
4.1 HDL CHOLESTEROL AS A THERAPEUTI  AGENT 
 
Increases in baseline HDL cholesterol levels via lifestyle changes may confer chronic 
protection against incidence and severity of IHD. Acute administration of reconstituted HDL 
cholesterol is also protective in animal models of ischaemia-reperfusion (206) which makes it 
an ideal candidate as a therapeutic agent. In human studies, reconstituted HDL cholesterol 
has been tested in pilot studies, and resulted in a positive modulating effect on the lipid 
profiles of diabetic patients (207), and on atherosclerotic plaques (208), (209). Whether or 
not the cardioprotection against ischaemia-reperfusion injury observed with reconstituted 
HDL cholesterol in the animal models translates to human models remains to be proved.  
 
4.2 S1P AS A THERAPEUTIC AGENT 
 
In in-vivo animal models, acute administration of S1P reduces infarct size (48). No clinical 
trials for acute or chronic administration of S1P in humans currently exist. However, an S1P 
receptor agonist, Fingolimod, is an approved drug in the treatment of multiple sclerosis 
(210). As such, S1P, or a pharmacological mimetic, may be a potential candidate for 
therapeutic intervention; however more research in this area is still required. The main 
therapeutic benefit of S1P may lie in its administration as a component of reconstituted HDL 
cholesterol. Reconstituted HDL cholesterol that has been tested in a clinical setting does not 
contain S1P (211). However, the composition of HDL cholesterol, not merely the quantity, is 















in the antiatherosclerotic effect of HDL cholesterol (46). Our data show that S1P and HDL 
cholesterol protect to a similar degree, suggesting that S1P may be the active component in 
the cardioprotective effect of HDL cholesterol. Therefore, any therapeutic HDL cholesterol 
























































Chapter 6: Limitations of the study, Further Work and 
Conclusion   
 
1: LIMITATIONS OF THE STUDY AND FURTHER WORK 
 
 The isolated perfused rat heart model, which was used for infarct size analysis and 
mitochondrial respiration analysis, only received S1P pretreatment, and not HDL 
cholesterol pretreatment. These experiments were conducted at the beginning of the 
MSc dissertation and at this stage the native HDL cholesterol from our collaborators in 
Geneva was unavailable. Once the HDL cholesterol became available, it was 
incorporated into all subsequent experiments with the intention to repeat the initial rat 
heart experiments with HDL cholesterol. However, due to availability of equipment and 
time constraints this was not possible. The native HDL cholesterol used in these 
experiments has since been validated by Dr. Miguel Frias in an isolated mouse heart 
model, where it is shown to reduce infarct size (197). 
 
 Respiratory function analysis of isolated rat heart mitochondria did not include ETC 
uncouplers, which would have given as a better idea of the maximal respiratory rates of 
the mitochondria. Further characterisation of isolated rat heart mitochondria would be 
beneficial in putting our results into context. 
 
 Analysis of mPTP opening was restricted to use of TMRM dye. A different model could 
be used to confirm these results. There are other dyes which can be used to measure 
mitochondrial depolarization, such as Mitotracker Red, however TMRM is the current 
gold standard. Therefore, indirect ways to measure opening of the mPTP could be used, 
such as a calcium retention assay or probing for cytochrome c release into the 
cytoplasm. 
 
 CsA was used as a positive control for inhibition of the mPTP, while CCCP was 
used as a negative control for mPTP opening. However, as with most 
pharmacological agents, it has limitations in terms of specificity.  
 The results obtained for S1P in the fluorescent microscopy model matched the 
results obtained with in the flow cytometer model. Unfortunately, a CsA group was 
not included in our experiments measuring the mPTP opening with the flow 
cytometer. The inclusion of a CsA group in this model is necessary to confirm its 
validity.  
 Another limitation of our study is that we did not include a group with S1P nor 
HDL in normoxic conditions.   
 
 The HDL cholesterol used was native HDL, and the exact composition was unknown. 
Therefore one is unable to say whether or not it was the S1P component of HDL 















with known concentrations of S1P is the focus of work done by our collaborators in 
Geneva (Dr Miguel Frias). 
 
 Administration of a known cardioprotective agent to the STAT-3 KO mice, which does 
not act via the SAFE pathway, such as cyclosporinA may be desirable to confirm that 
STAT-3 KO mice are capable of being protected and that they do still have a functional 
mPTP. 
 
 As with all animal models, there is a limit on physiological translation to humans. 
Furthermore, because isolated hearts and isolated cardiomyocytes were used, it is not a 
true representation of all physiological processes. For example, the liver plays a vital role 
in regulation of cholesterol levels, and it is unknown if supplementation with S1P or HDL 
cholesterol would be metabolized by the liver. Therefore, translating these results into an 
in vivo model is a potential area for further studies. 
 
 S1P increased phosphorylation of STAT-3 at the serine residue in the mitochondria, yet 
HDL cholesterol had no effect. In order to resolve this discrepancy different time points of 
protein harvest could be investigated to get an idea of changes in STAT-3 state over 
time following treatment with S1P or HDL cholesterol. Furthermore, western blot analysis 
only looked at total STAT-3 and the serine phosphorylated isoform in the mitochondrial 
fraction. Expanding this to include cytosolic and nuclear fractions, as well as the 
phosphorylated tyrosine isoform, might illuminate HDL cholesterols effect on STAT-3 
signalling.  
 
 Administration of both HDL cholesterol and S1P was followed by a wash out 
period in all models which does not represent a physiological model. Whether the 
30 minutes of washout is truly necessary for the protection or whether 60 minutes 





Our data confirms the cardioprotective effects of both S1P and HDL cholesterol against 
hypoxia (213). Furthermore, we demonstrated that both HDL cholesterol and S1P protect the 
cardiomyocytes via inhibition of mPTP opening, achieved via activation of the SAFE 
pathway. These results strongly suggest that both HDL cholesterol and S1P are ideal 
candidates for therapeutic treatment of CVD, either via acute administration or chronic 

















Figure 45: Proposed signalling cascade in S1P and HDL cholesterol induced cardioprotection. Both S1P 
and HDL cholesterol are cytoprotective. This protection is mediated via the SAFE pathway. S1P and HDL 
cholesterol inhibit mPTP opening, which is also mediated via the SAFE pathway. Migration of STAT-3 



































NaCl    118.8mM   
NaHCO3   25mM   
Glucose  11.1mM   
KCl    4.75mM   
MgSO4.7H2O  1.19mM   
KH2PO4   1.18mM   
CaCl2.2H2O   1.35mM   
 
Oxygenate with 95% O2 and 5% CO2 
 
Sodium Phosphate Buffer 
Solution 1: 
NaH2PO4.2H2O 100mM   
 
Solution 2: 
Na2HPO4  100mM   
 































Sucrose   250mM  
HEPES   10mM  
K-EGTA   5mM  
 
BSA Buffer 
Wash buffer + 0.5% fatty acid free BSA 
 
Percoll Buffer 
Sucrose   250mM  
HEPES   10mM  
K-EGTA   5mM  
 
Make up to 740ml instead of a litre (or 100-percent concentration of desired Percoll gradient) 
 
Percoll Gradient 
Percoll   26ml  
Percoll Buffer   74ml  
 
EGTA-free Buffer 
Sucrose  250mM 
HEPES  10mM 
 
Buffer A 
Sucrose  250mM 
TrisHCl  20mM  

































0.2M NaOH made up to 400ml, instead of 1000ml 
Add, in order:  
NaTartrate   9g  
CuSO4.5H2O   3g  
KI   5g 






























































KCl   120mM   
KH2PO4  5mM   
MOPS   5mM    
EGTA    1mM    
 
Saturated KCl 


























































NaCl     113mM 
KCl     4.7 mM 
KH2PO4    0.6 mM 
Na2HPO4    0.6 mM 
MgSO4.7H2O    1.2 mM 
NaHCO3    12 mM 
KHCO3    10 mM 
Taurine     30 mM 
HEPES    10 mM 
Glucose    11 mM 
2,3 Butanedione monoxime  10 mM 
 
Perfusion Buffer 2 
Perfusion Buffer   50ml 
CaCl2      12.5µM 
Bovine Serum Albumin  1% 
 
Collagenase Buffer 
Perfusion Buffer 2   50ml 
Collagenase (type 2, ~318U/mg) 0.045g 
NB:May need to adjust collagenase according to the stock U/mg strength 
 
Calcium Reintroduction 
Reintroduce calcium in a step wise fashion (lay the tube horizontal) 
10ul of 0.1M CaCl2 for 4 minutes 
10ul of 0.1M CaCl2 for 4 minutes 
20ul of 0.1M CaCl2 for 4 minutes 
30ul of 0.1M CaCl2 for 4 minutes 
30ul of 0.1M CaCl2 for 4 minutes 
 
Medium 199 
M-199     500ml 
BSA     1g 
Creatine     0.33g 
Taurine     0.31g 
Carnitine     0.16g 
Pen/Strep    1% 
 
Laminin  



















NaCl   137 mM  
KCl   12 mM   
MgCl2.6H2O  0.5 mM  
CaCl2.2H2O  0.9 mM  
HEPES  20 mM   
2-DG   20 mM   
 
pH to 6.4 
























































      
Running Gel 
For 2 gels:     
dH2O     9.8ml 
1.5M Tris HCl pH 8.8    5ml 
20% SDS    100ul 
Acrylamide    5ml 
10% APS    100ul 
TEMED    40ul 
 
Stacking Gel 
For 2 gels: 
dH20     7.5ml 
0.5 M Tris Hcl pH 6.8   3ml 
20% SDS    60ul 
Acrylamide    1.5ml 
10% APS    80ul 
TEMED    40ul 
 
10x Running Buffer 
Tris    60.6g 
Glycine   288g 
SDS    20g 
dH2O    up to 2L 
 
Transfer Buffer 
Tris    3.03g 
Glycine   14.4g 
Methanol   200ml 
dH20    Make up to 1L 
 
TBS-T  
Tris    2.42g 
NaCl    8g 
Tween20   1ml 
dH20    make up to 1L 




rabbit 1:4000 in TBS-T with 5% milk 
Secondary 

















1:3000 rabbit in TBS-T 
Secondary 




1:2000 rabbit in TBS-T 
Secondary 




1:1000 Goat in TBS-T 
Secondary 
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